Product Sales Data From Annual Reports of Major Pharmaceutical Companies // 2017

Manostaxx
Manostaxx

http://www.manostaxx.com

Abbvie Humira Adalimumab Immunology (Organ Transplant, Arthritis etc.) USD Millions 18,427 16,078 18,427 16,078 2,349 15
Abbvie Androgel Testosterone Hormonal Disorders USD Millions 577 675 577 675 -98 -15
Abbvie Kaletra Lopinavir/Ritonavir Infectious Diseases (HIV, Hepatitis etc.) USD Millions 423 549 423 549 -126 -23
Abbvie Synagis Palivizumab Respiratory Disorders USD Millions 738 730 738 730 8 1
Abbvie Lupron Leuprolide Acetate Oncology USD Millions 829 821 829 821 8 1
Abbvie Synthroid Levothyroxine Sodium Hormonal Disorders USD Millions 781 763 781 763 18 2
Abbvie Sevoflurane Sevoflurane Anaesthetic USD Millions 410 428 410 428 -18 -4
Abbvie Creon Pancrelipase Rare Diseases USD Millions 831 730 831 730 101 14
Abbvie Duodopa Carbidopa/Levodopa Neurological/Mental Disorders USD Millions 355 293 355 293 62 21
Abbvie HCV Infectious Diseases (HIV, Hepatitis etc.) USD Millions 1,274 1,522 1,274 1,522 -248 -16
Abbvie Imbruvica Ibrutinib Oncology USD Millions 2,573 1,832 2,573 1,832 741 40
Abbvie Others USD Millions 998 1,217 998 1,217 -219 -18
Abbvie Total Sales USD Millions 28,216 25,638 28,216 25,638 2,578 10
Abbott Pediatric USD Millions 3,889 3,883 3,889 3,883 6 0.2
Abbott Adult USD Millions 3,036 3,016 3,036 3,016 20 1
Abbott Total Nutrition USD Millions 6,925 6,899 6,925 6,899 26 0.4
Abbott Core Laboratory USD Millions 4,063 3,844 4,063 3,844 219 6
Abbott Molecular USD Millions 463 456 463 456 7 2
Abbott Point of Care USD Millions 550 513 550 513 37 7
Abbott Rapid Diagnostics USD Millions 540 Not Available 540 Not Available 540 Not Available
Abbott Total Diagnostics USD Millions 5,616 4,813 5,616 4,813 803 17
Abbott Key Emerging Markets USD Millions 3,307 2,912 3,307 2,912 395 14
Abbott Others USD Millions 980 947 980 947 33 3
Abbott Total Established Pharmaceuticals USD Millions 4,287 3,859 4,287 3,859 428 11
Abbott Cardiovascular and Neuromodulation USD Millions 8,911 2,896 8,911 2,896 6,015 208
Abbott Other Sales USD Millions 1,651 2,386 1,651 2,386 -735 -31
Abbott Total Sales USD Millions 27,390 20,853 27,390 20,853 6,537 31
Allergan Botox Onabotulinumtoxin A Urology USD Millions 3,169 2,786 3,169 2,786 383 14
Allergan Restasis Cyclosporine Immunology (Organ Transplant, Arthritis etc.) USD Millions 1,474 1,488 1,474 1,488 -14 -1
Allergan Fillers USD Millions 1,042 867 1,042 867 175 20
Allergan Lumigan/Ganfort Bimatoprost Ophthalmology USD Millions 689 688 689 688 1 0.1
Allergan Linzess/Constella Linaclotide Gastrointestinal Disorders USD Millions 723 643 723 643 80 12
Allergan Bystolic/Byvalson Nebivolol Cardiovascular Diseases USD Millions 614 641 614 641 -27 -4
Allergan Namenda XR Memantine Hydrochloride Alzheimer Disease USD Millions 453 628 453 628 -175 -28
Allergan Alphagan/Combigan Brimonidine Tartrate/Timolol Maleate Ophthalmology USD Millions 552 546 552 546 6 1
Allergan Eye Drops Ophthalmology USD Millions 481 463 481 463 18 4
Allergan Asacol/Delzicol Mesalazine Gastrointestinal Disorders USD Millions 246 415 246 415 -169 -41
Allergan Lo Loestrin Norethindrone Acetate/Ethinyl estradiol Sexual Health USD Millions 459 404 459 404 56 14
Allergan EstraceCream Estradiol Sexual Health USD Millions 367 379 367 379 -12 -3
Allergan Breast Implants USD Millions 400 356 400 356 44 12
Allergan Viibryd/Fetzima Vilazodone Neurological/Mental Disorders USD Millions 336 342 336 342 -6 -2
Allergan Minastrin24 Ethinyl Estradiol, Norethindrone Sexual Health USD Millions 61 327 61 327 -266 -81
Allergan Ozurdex Dexamethasone Ophthalmology USD Millions 312 263 312 263 49 18
Allergan Carafate /Sulcrate Sucralfate Gastrointestinal Disorders USD Millions 239 231 239 231 8 3
Allergan Aczone Dapsone Dermatology USD Millions 167 217 167 217 -50 -23
Allergan Zenpep Pancrelipase Gastrointestinal Disorders USD Millions 212 201 212 201 11 6
Allergan Canasa/Salofalk Mesalazine Gastrointestinal Disorders USD Millions 181 196 181 196 -15 -8
Allergan Saphris Asenapine Neurological/Mental Disorders USD Millions 155 167 155 167 -12 -7
Allergan Armour Thyroid Thyroid Extract Hypothyroidism USD Millions 169 167 169 167 3 2
Allergan Teflaro Ceftaroline Dermatology USD Millions 122 134 122 134 -12 -9
Allergan Rapaflo Silodosin Renal Disorders USD Millions 115 122 115 122 -7 -6
Allergan SkinMedica Dermatology USD Millions 101 108 101 108 -7 -7
Allergan Savella Milnacipran HCl Fibromyalgia USD Millions 98 103 98 103 -5 -5
Allergan Tazorac Tazarotene Dermatology USD Millions 66 96 66 96 -30 -31
Allergan Vraylar Cariprazine Neurological/Mental Disorders USD Millions 289 94 289 94 195 206
Allergan Viberzi Eluxadoline Gastrointestinal Disorders USD Millions 157 93 157 93 64 68
Allergan Latisse Bimatoprost Hypotrichosis of Eyelashes USD Millions 65 86 65 86 -21 -25
Allergan Lexapro Escitalopram oxalate Neurological/Mental Disorders USD Millions 52 67 52 67 -15 -22
Allergan Namzaric Memantine and Donepezil Hydrochloride Neurological/Mental Disorders USD Millions 131 58 131 58 74 128
Allergan Kybella/Belkyra Deoxycholic Acid Submental Fat USD Millions 56 53 56 53 4 7
Allergan Dalvance Dalbavancin Dermatology USD Millions 56 39 56 39 17 42
Allergan Avycaz Ceftazidime and Avibactam Gastrointestinal Disorders USD Millions 61 36 61 36 25 69
Allergan Liletta Levonorgestrel Sexual Health USD Millions 38 23 38 23 15 63
Allergan Enablex Darifenacin Renal Disorders USD Millions 4 17 4 17 -13 -77
Allergan Namenda IR Memantine Hydrochloride Alzheimer Disease USD Millions 0.1 15 0.1 15 -15 -99
Allergan Other Revenues USD Millions 1,372 1,091 1,372 1,091 281 26
Allergan Less product sold through our former ANDA Distribution business USD Millions Not Available -80 Not Available -80 -80 100
Allergan Total Net Revenues USD Millions 15,941 14,571 15,941 14,571 1,370 9
Alexion Soliris Eculizumab Blood Disorders USD Millions 3,144 2,843 3,144 2,843 301 11
Alexion Strensiq Asfotase Alfa Metabolic Disorders USD Millions 340 210 340 210 130 62
Alexion Kanuma Sebelipase Alfa Metabolic Disorders USD Millions 66 29 66 29 37 126
Alexion Others USD Millions 2 2 2 2 0 -20
Alexion Total Net Product Sales USD Millions 3,551 3,084 3,551 3,084 467 15
Amgen Neulasta Pegfilgrastim Blood Disorders USD Millions 4,534 4,648 4,534 4,648 -114 -2
Amgen Neupogen Filgrastim Blood Disorders USD Millions 549 765 549 765 -216 -28
Amgen Enbrel Etanercept Immunology (Organ Transplant, Arthritis etc.) USD Millions 5,433 5,965 5,433 5,965 -532 -9
Amgen Xgeva Denosumab Oncology USD Millions 1,575 1,529 1,575 1,529 46 3
Amgen Prolia Denosumab Bone and Joint Diseases USD Millions 1,968 1,635 1,968 1,635 333 20
Amgen Epogen Epoetin Alfa Blood Disorders USD Millions 1,096 1,282 1,096 1,282 -186 -15
Amgen Aranesp Darbepoetin Alfa Blood Disorders USD Millions 2,053 2,093 2,053 2,093 -40 -2
Amgen Sensipar/Mimpara Cinacalcet Hormonal Disorders USD Millions 1,718 1,582 1,718 1,582 136 9
Amgen Vectibix Panitumumab Oncology USD Millions 642 611 642 611 31 5
Amgen Nplate Romiplostim Immunology (Organ Transplant, Arthritis etc.) USD Millions 642 584 642 584 58 10
Amgen Kyprolis Carfilzomib Oncology USD Millions 835 692 835 692 143 21
Amgen Blincyto Blinatumomab Oncology USD Millions 175 115 175 115 60 52
Amgen Repatha Evolocumab Cardiovascular Diseases USD Millions 319 141 319 141 178 126
Amgen Others USD Millions 256 250 256 250 6 2
Amgen Total Pharmaceuticals USD Millions 21,795 21,892 21,795 21,892 -97 -0.4
Amgen Other Revenues USD Millions 1,054 1,099 1,054 1,099 -45 -4
Amgen Total Revenues USD Millions 22,849 22,991 22,849 22,991 -142 -1
AstraZeneca Crestor Rosuvastatin Calcium Cardiovascular Diseases USD Millions 2,365 3,401 2,365 3,401 -1,036 -30
AstraZeneca Seloken/Toprol-XL Metoprolol Hydrochloride Cardiovascular Diseases USD Millions 695 737 695 737 -42 -6
AstraZeneca Onglyza/Kombiglyze XR/Komboglyze Saxagliptin/Saxagliptin + Metoprolol Hydrochloride Diabetes USD Millions 611 720 611 720 -109 -15
AstraZeneca Atacand Candesartan Cardiovascular Diseases USD Millions 300 315 300 315 -15 -5
AstraZeneca Brilinta/Brilique Ticagrelor Cardiovascular Diseases USD Millions 1,079 839 1,079 839 240 29
AstraZeneca Byetta Exenatide Diabetes USD Millions 176 254 176 254 -78 -31
AstraZeneca Bydureon Exenatide Diabetes USD Millions 574 578 574 578 -4 -1
AstraZeneca Farxiga/Forxiga Dapagliflozin Diabetes USD Millions 1,074 835 1,074 835 239 29
AstraZeneca Symlin Pramlintide Acetate Diabetes USD Millions 48 0 48 0 48 New Launch
AstraZeneca Qtern Dapagliflozin/Saxagliptin Diabetes USD Millions 5 0 5 0 5 New Launch
AstraZeneca Other Products USD Millions 339 437 339 437 -98 -22
AstraZeneca Total Cardiovascular and Metabolic Diseases USD Millions 7,266 8,116 7,266 8,116 -850 -10
AstraZeneca Zoladex Goserelin Acetate Oncology USD Millions 735 816 735 816 -81 -10
AstraZeneca Faslodex Fulvestrant Oncology USD Millions 941 830 941 830 111 13
AstraZeneca Iressa Gefitinib Oncology USD Millions 528 513 528 513 15 3
AstraZeneca Arimidex Anastrozole Oncology USD Millions 217 232 217 232 -15 -6
AstraZeneca Casodex Bicalutamide Oncology USD Millions 215 247 215 247 -32 -13
AstraZeneca Lynparza Olaparib Oncology USD Millions 297 218 297 218 79 36
AstraZeneca Tagrisso Osimertinib Oncology USD Millions 955 423 955 423 532 126
AstraZeneca Imfinzi Durvalumab Oncology USD Millions 19 0 19 0 19 New Launch
AstraZeneca Calquence Acalabrutinib Oncology USD Millions 3 0 3 0 3 New Launch
AstraZeneca Other Products USD Millions 114 104 114 104 10 10
AstraZeneca Total Oncology USD Millions 4,024 3,383 4,024 3,383 641 19
AstraZeneca Symbicort Budesonide and Formoterol Respiratory Disorders USD Millions 2,803 2,989 2,803 2,989 -186 -6
AstraZeneca Pulmicort Budesonide Respiratory Disorders USD Millions 1,176 1,061 1,176 1,061 115 11
AstraZeneca Tudorza/Eklira Aclidinium Bromide Respiratory Disorders USD Millions 150 170 150 170 -20 -12
AstraZeneca Daliresp/Daxas Roflumilast Respiratory Disorders USD Millions 198 154 198 154 44 29
AstraZeneca Duaklir Aclidinium Bromide/Formoterol Fumarate Respiratory Disorders USD Millions 79 63 79 63 16 25
AstraZeneca Bevespi Glycopyrrolate/Formoterol Fumarate Respiratory Disorders USD Millions 16 0 16 0 16 New Launch
AstraZeneca Other Products USD Millions 284 316 284 316 -32 -10
AstraZeneca Total Respiratory, Inflammation and Autoimmunity USD Millions 4,706 4,753 4,706 4,753 -47 -1
AstraZeneca Synagis Palivizumab Respiratory Disorders USD Millions 687 677 687 677 10 1
AstraZeneca FluMist/Fluenz Influenza Vaccine Live, Intranasal Infectious Diseases (HIV, Hepatitis etc.) USD Millions 78 104 78 104 -26 -25
AstraZeneca Movantik/Moventig Naloxegol Gastrointestinal Disorders USD Millions 122 91 122 91 31 34
AstraZeneca Seroquel XR Quetiapine Fumarate Neurological/Mental Disorders USD Millions 332 735 332 735 -403 -55
AstraZeneca Nexium Esomeprazole Magnesium Gastrointestinal Disorders USD Millions 1,952 2,032 1,952 2,032 -80 -4
AstraZeneca Losec/Prilosec Omeprazole Gastrointestinal Disorders USD Millions 271 276 271 276 -5 -2
AstraZeneca Other Products USD Millions 714 1,152 714 1,152 -438 -38
AstraZeneca Total Other USD Millions 4,156 5,067 4,156 5,067 -911 -18
AstraZeneca Total Product Sales USD Millions 20,152 21,319 20,152 21,319 -1,167 -5
AstraZeneca Total Externalisation Revenues USD Millions 2,313 1,683 2,313 1,683 630 37
AstraZeneca Total Revenues USD Millions 22,465 23,002 22,465 23,002 -537 -2
Astellas Pharma Symbicort Budesonide and Formoterol Respiratory Disorders YEN Millions 39,700 38,400 381 369 12 3
Astellas Pharma Xtandi Enzalutamide Oncology YEN Millions 269,240 253,200 2,585 2,431 154 6
Astellas Pharma Lipitor Atorvastatin Calcium Cardiovascular Diseases YEN Millions 20,600 24,600 198 236 -38 -16
Astellas Pharma Prograf Tacrolimus Immunology (Organ Transplant, Arthritis etc.) YEN Millions 153,900 188,300 1,477 1,808 -330 -18
Astellas Pharma Vesicare Solifenacin Succinate Renal Disorders YEN Millions 98,290 120,100 944 1,153 -209 -18
Astellas Pharma Ambisome Amphotericin B Infectious Diseases (HIV, Hepatitis etc.) YEN Millions 10,810 10,500 104 101 3 3
Astellas Pharma Micardis Telmisartan Cardiovascular Diseases YEN Millions 60,200 93,700 578 900 -322 -36
Astellas Pharma Betanis/Myrbetriq/Beiga Mirabegron Renal Disorders YEN Millions 111,480 93,200 1,070 895 175 20
Astellas Pharma Seroquel Quetiapine Fumarate Neurological/Mental Disorders YEN Millions 6,500 8,000 62 77 -14 -19
Astellas Pharma Adenoscan/Lexiscan Adenosine/Regadenoson Diagnostic YEN Millions 69,760 69,900 670 671 -1 -0.2
Astellas Pharma Myslee Zolpidem Neurological/Mental Disorders YEN Millions 13,600 15,300 131 147 -16 -11
Astellas Pharma Celecox Celecoxib Anti-inflammatory YEN Millions 48,400 47,600 465 457 8 2
Astellas Pharma Harnal/Omnic Tamsulosin Renal Disorders YEN Millions 26,500 47,300 254 454 -200 -44
Astellas Pharma Funguard/Mycamine Micafungin Sodium Anti-fungal YEN Millions 34,070 40,300 327 387 -60 -15
Astellas Pharma Tarceva Erlotinib Oncology YEN Millions 30,000 36,800 288 353 -65 -18
Astellas Pharma Vaccines Vaccines Vaccine YEN Millions 29,200 34,100 280 327 -47 -14
Astellas Pharma Eligard Leuprorelin Oncology YEN Millions 16,560 16,000 159 154 5 4
Astellas Pharma Protopic Tacrolimus Immunology (Organ Transplant, Arthritis etc.) YEN Millions 0 3,500 0 34 -34 -100
Astellas Pharma Bonoteo Minodronic Acid Bone and Joint Diseases YEN Millions 13,500 13,900 130 133 -4 -3
Astellas Pharma Gaster Famotidine Gastrointestinal Disorders YEN Millions 2,200 11,400 21 109 -88 -81
Astellas Pharma Geninax Garenoxacin Anti-bacterial YEN Millions 9,400 10,100 90 97 -7 -7
Astellas Pharma Suglat Ipragliflozin Diabetes YEN Millions 11,800 9,100 113 87 26 30
Astellas Pharma Cimzia Certolizumab Pegol Anti-inflammatory YEN Millions 8,800 7,600 84 73 12 16
Astellas Pharma Argamate Calcium Polystyrene Sulphonate Hyperkalemia YEN Millions 5,800 5,900 56 57 -1 -2
Astellas Pharma Cresemba Isavuconazonium Sulfate Anti-fungal YEN Millions 8,070 5,000 77 48 29 61
Astellas Pharma Gonax Degarelix Acetate Oncology YEN Millions 4,700 4,300 45 41 4 9
Astellas Pharma Dificlir Fidaxomicin Infectious Diseases (HIV, Hepatitis etc.) YEN Millions 0 2,200 0 21 -21 -100
Astellas Pharma Repatha Evolocumab Cardiovascular Diseases YEN Millions 1,100 0 11 0 11 New Launch
Astellas Pharma Linzess Linaclotide Gastrointestinal Disorders YEN Millions 900 0 9 0 9 New Launch
Astellas Pharma Qutenza Capasaicin Neuropathic Pain YEN Millions 0 2,000 0 19 -19 -100
Astellas Pharma Kiklin Bixalomer Renal Disorders YEN Millions 0 1,600 0 15 -15 -100
Astellas Pharma Product Sales YEN Millions 1,105,080 1,213,900 10,609 11,653 -1,045 -9
Astellas Pharma Others YEN Millions 46,000 98,700 442 948 -506 -53
Astellas Pharma Total Sales YEN Millions 1,151,170 1,312,600 11,051 12,601 -1,550 -12
Bayer Xarelto Rivaroxaban Cardiovascular Diseases EURO Millions 3,298 2,928 4,090 3,631 459 13
Bayer Eylea Aflibercept Ophthalmology EURO Millions 1,880 1,625 2,331 2,015 316 16
Bayer Xofigo Radium Ra 223 Dichloride Oncology EURO Millions 408 331 506 410 95 23
Bayer Stivarga Regorafenib Oncology EURO Millions 315 275 391 341 50 15
Bayer Adempas Riociguat Cardiovascular Diseases EURO Millions 295 254 366 315 51 16
Bayer Subtotal Key growth products EURO Millions 6,196 5,413 7,683 6,712 971 14
Bayer Mirena product family Levonorgestrel Sexual Health EURO Millions 1,126 1,043 1,396 1,293 103 8
Bayer Kogenate Antihemophilic Factor (Recombinant) Rare Diseases EURO Millions 967 1,166 1,199 1,446 -247 -17
Bayer Nexavar Sorafenib Oncology EURO Millions 834 870 1,034 1,079 -45 -4
Bayer Betaferon/Betaseron Interferon Beta-1b Neurological/Mental Disorders EURO Millions 651 734 807 910 -103 -11
Bayer Adalat Nifedipine Cardiovascular Diseases EURO Millions 648 624 804 774 30 4
Bayer YAZ/Yasim/Yasminelle Drospirenone and Ethinyl Estradiol Sexual Health EURO Millions 648 678 804 841 -37 -4
Bayer Aspirin Cardio Acetylsalicylic Acid Cardiovascular Diseases EURO Millions 581 538 720 667 53 8
Bayer Glucobay Acarbose Diabetes EURO Millions 563 515 698 639 60 9
Bayer Gadavist/Gadovist Ezetimibe Cardiovascular Diseases EURO Millions 365 346 453 429 24 5
Bayer Avalox/Avelox Moxifloxacin Hydrochloride Anti-bacterial EURO Millions 333 353 413 438 -25 -6
Bayer Total Best-selling products EURO Millions 12,912 12,280 16,011 15,227 784 5
Bayer Total Pharmaceuticals EURO Millions 16,847 16,420 20,890 20,361 529 3
Bayer Consumer Health EURO Millions 5,862 6,037 7,269 7,486 -217 -3
Bayer Crop Science EURO Millions 9,577 9,915 11,875 12,295 -419 -3
Bayer Animal Health EURO Millions 1,571 1,523 1,948 1,889 60 3
Bayer Total Life Science (Incl. Reconciliation) EURO Millions 35,015 34,943 43,419 43,329 89 0.2
Bayer Covestro EURO Millions 10,556 11,826 13,089 14,664 -1,575 -11
Bayer Total Group Sales EURO Millions 45,571 46,769 56,508 57,994 -1,486 -3
Baxter Renal Care USD Millions 3,480 3,421 3,480 3,421 59 2
Baxter Acute Therapies USD Millions 456 429 456 429 27 6
Baxter Medication Delivery USD Millions 2,698 2,596 2,698 2,596 102 4
Baxter Pharmaceuticals USD Millions 1,883 1,722 1,883 1,722 161 9
Baxter Nutrition USD Millions 882 858 882 858 24 3
Baxter Advanced Surgery USD Millions 707 690 707 690 17 2
Baxter Others USD Millions 455 447 455 447 8 2
Baxter Total Revenues USD Millions 10,561 10,163 10,561 10,163 398 4
Biogen Tecfidera Dimethyl Fumarate Neurological/Mental Disorders USD Millions 4,214 3,968 4,214 3,968 246 6
Biogen Avonex Interferon Beta-1a Neurological/Mental Disorders USD Millions 2,152 2,314 2,152 2,314 -162 -7
Biogen Plegridy Peginterferon Beta-1a Neurological/Mental Disorders USD Millions 494 482 494 482 13 3
Biogen Tysabri Natalizumab Neurological/Mental Disorders USD Millions 1,973 1,964 1,973 1,964 9 0.5
Biogen Fampyra Fampridine Neurological/Mental Disorders USD Millions 92 85 92 85 7 8
Biogen Zinbryta Daclizumab Neurological/Mental Disorders USD Millions 53 8 53 8 45 576
Biogen Total Multiple Sclerosis USD Millions 8,977 8,820 8,977 8,820 157 2
Biogen Eloctate Antihemophilic Factor (Recombinant), Fc Fusion Protein Blood Disorders USD Millions 48 513 48 513 -465 -91
Biogen Alprolix Coagulation Factor IX (Recombinant), Fc Fusion Protein Blood Disorders USD Millions 26 334 26 334 -308 -92
Biogen Hemophilia USD Millions 74 847 74 847 -773 -91
Biogen Spinraza Nusinersen Spinal Muscular Atrophy USD Millions 884 5 884 5 879 19,111
Biogen Spinal Muscular Atrophy USD Millions 884 5 884 5 879 19,111
Biogen Benepali Etanercept Immunology (Organ Transplant, Arthritis etc.) USD Millions 371 101 371 101 270 269
Biogen Flixabi Infliximab  Rheumatoid Arthritis USD Millions 9 0.1 9 0.1 9 8,900
Biogen Fumaderm Dimethyl Fumarate Anti-fungal USD Millions 40 46 40 46 -6 -14
Biogen Other Product Revenues USD Millions 419 147 419 147 272 185
Biogen Total Product Revenues USD Millions 10,355 9,818 10,355 9,818 536 5
Biogen Anti-CD20 Revenues USD Millions 1,559 1,315 1,559 1,315 244 19
Biogen Other Revenues USD Millions 360 316 360 316 44 14
Biogen Total Sales USD Millions 12,274 11,450 12,274 11,450 824 7
Biomarin Aldurazyme Laronidase Rare Diseases USD Millions 90 94 90 94 -4 -4
Biomarin Brineura Cerliponase Alfa Rare Diseases USD Millions 9 0 9 0 9 New Launch
Biomarin Firdapse Amifampridine Rare Diseases USD Millions 19 18 19 18 1 4
Biomarin Kuvan Sapropterin Dihydrochloride Hyperphenylalaninemia USD Millions 408 348 408 348 60 17
Biomarin Naglazyme Galsulfase Rare Diseases USD Millions 332 297 332 297 36 12
Biomarin Vimizim Elosulfase Alfa Rare Diseases USD Millions 413 354 413 354 59 17
Biomarin Net Product Revenues USD Millions 1,270 1,110 1,270 1,110 160 14
Biomarin Royalty and Other Revenues USD Millions 43 7 43 7 37 565
Biomarin Total Revenues USD Millions 1,314 1,117 1,314 1,117 197 18
Bristol Myers Squibb Baraclude Entecavir Infectious Diseases (HIV, Hepatitis etc.) USD Millions 1,052 1,192 1,052 1,192 -140 -12
Bristol Myers Squibb Hepatits C Franchise Daclatasvir and Asunaprevir Infectious Diseases (HIV, Hepatitis etc.) USD Millions 406 1,578 406 1,578 -1,172 -74
Bristol Myers Squibb Reyataz Atazanavir Sulphate Infectious Diseases (HIV, Hepatitis etc.) USD Millions 698 912 698 912 -214 -23
Bristol Myers Squibb Sustiva Efavirenz Infectious Diseases (HIV, Hepatitis etc.) USD Millions 729 1,065 729 1,065 -336 -32
Bristol Myers Squibb Total Virology USD Millions 2,885 4,747 2,885 4,747 -1,862 -39
Bristol Myers Squibb Empliciti Elotuzumab Oncology USD Millions 231 150 231 150 81 54
Bristol Myers Squibb Opdivo Nivolumab Oncology USD Millions 4,948 3,774 4,948 3,774 1,174 31
Bristol Myers Squibb Sprycel Dasatinib Oncology USD Millions 2,005 1,824 2,005 1,824 181 10
Bristol Myers Squibb Yervoy Ipilimumab Oncology USD Millions 1,244 1,053 1,244 1,053 191 18
Bristol Myers Squibb Total Oncology USD Millions 8,428 6,801 8,428 6,801 1,627 24
Bristol Myers Squibb Orencia Abatacept Immunology (Organ Transplant, Arthritis etc.) USD Millions 2,479 2,265 2,479 2,265 214 9
Bristol Myers Squibb Total Immunoscience USD Millions 2,479 2,265 2,479 2,265 214 9
Bristol Myers Squibb Eliquis Apixaban Cardiovascular Diseases USD Millions 4,872 3,343 4,872 3,343 1,529 46
Bristol Myers Squibb Total Cardiovascular USD Millions 4,872 3,343 4,872 3,343 1,529 46
Bristol Myers Squibb Total Other Mature Products USD Millions 2,112 2,271 2,112 2,271 -159 -7
Bristol Myers Squibb Total Pharmaceuticals USD Millions 20,776 19,427 20,776 19,427 1,349 7
Celgene Revlimid Lenalidomide Oncology USD Millions 8,187 6,974 8,187 6,974 1,213 17
Celgene Abraxane Paclitaxel Protein Bound Oncology USD Millions 992 973 992 973 19 2
Celgene Pomalyst/Imnovid Pomalidomide Oncology USD Millions 1,614 1,311 1,614 1,311 303 23
Celgene Otezla Apremilast Dermatology USD Millions 1,279 1,017 1,279 1,017 262 26
Celgene Vidaza Azacitidine Oncology USD Millions 628 608 628 608 20 3
Celgene Azacitidine for Injection Azacitidine Oncology USD Millions 36 66 36 66 -30 -45
Celgene Thalomid Thalidomide Oncology USD Millions 132 152 132 152 -20 -13
Celgene Idhifa Enasidenib Oncology USD Millions 20 0 20 0 20 New Launch
Celgene Istodax Romidepsin Oncology USD Millions 76 80 76 80 -4 -5
Celgene Others USD Millions 9 4 9 4 5 109
Celgene Total Net Product Sales USD Millions 12,973 11,185 12,973 11,185 1,788 16
Celgene Other Revenues USD Millions 30 45 30 45 -15 -33
Celgene Total Revenues USD Millions 13,003 11,229 13,003 11,229 1,774 16
Chugai Pharmaceuticals Oncology YEN Millions 225,900 220,300 2,169 2,115 54 3
Chugai Pharmaceuticals Bone and Joint Diseases YEN Millions 93,300 86,100 896 827 69 8
Chugai Pharmaceuticals Renal Diseases YEN Millions 39,300 41,100 377 395 -17 -4
Chugai Pharmaceuticals Others YEN Millions 29,900 32,200 287 309 -22 -7
Chugai Pharmaceuticals Tamiflu Sales Oseltamivir Phosphate Anti-viral YEN Millions 16,900 13,500 162 130 33 25
Chugai Pharmaceuticals Ordinary use YEN Millions 11,900 12,000 114 115 -1 -1
Chugai Pharmaceuticals Government stockpiles YEN Millions 5,000 1,500 48 14 34 233
Chugai Pharmaceuticals Overseas YEN Millions 94,000 79,500 902 763 139 18
Chugai Pharmaceuticals Domestic sales (excluding Tamiflu) YEN Millions 388,400 379,700 3,729 3,645 84 2
Chugai Pharmaceuticals Total Sales YEN Millions 499,300 472,700 4,793 4,538 255 6
Chugai Pharmaceuticals Royalties and Other Operating Income YEN Millions 34,900 19,100 335 183 152 83
Chugai Pharmaceuticals Total Revenues YEN Millions 534,200 491,800 5,128 4,721 407 9
Daiichi Sankyo Nexium Esomeprazole Gastrointestinal Disorders YEN Millions 87,800 86,600 843 831 12 1
Daiichi Sankyo Memary Memantine Alzheimer Disease YEN Millions 46,000 48,600 442 467 -25 -5
Daiichi Sankyo Olmetec Olmesartan Medoxomil Cardiovascular Diseases YEN Millions 67,500 55,800 648 536 112 21
Daiichi Sankyo Lixiana Edoxaban Blood Disorders YEN Millions 28,970 64,290 278 617 -339 -55
Daiichi Sankyo Loxonin Loxoprofen Anti-inflammatory YEN Millions 39,200 37,100 376 356 20 6
Daiichi Sankyo Tenelia Teneligliptin Diabetes YEN Millions 24,300 25,400 233 244 -11 -4
Daiichi Sankyo Pralia Denosumab Bone and Joint Diseases YEN Millions 16,700 22,000 160 211 -51 -24
Daiichi Sankyo Rezaltas Olmesartan Medoxomil/Azelnidipine Cardiovascular Diseases YEN Millions 17,700 17,000 170 163 7 4
Daiichi Sankyo Ranmark Denosumab Bone and Joint Diseases YEN Millions 13,600 15,000 131 144 -13 -9
Daiichi Sankyo Efient Prasugrel Blood Disorders YEN Millions 38,568 35,506 370 341 29 9
Daiichi Sankyo Inavir Laninamivir Anti-influenza YEN Millions 19,400 20,900 186 201 -14 -7
Daiichi Sankyo Cravit Levofloxacin Anti-bacterial YEN Millions 15,800 13,200 152 127 25 20
Daiichi Sankyo Urief Silodosin Urology YEN Millions 11,700 11,200 112 108 5 4
Daiichi Sankyo Omnipaque Iohexol Contrast Medium YEN Millions 14,700 14,100 141 135 6 4
Daiichi Sankyo Mevalotin Pravastatin Cardiovascular Diseases YEN Millions 11,000 9,200 106 88 17 20
Daiichi Sankyo Welchol Colesevelam Blood Disorders YEN Millions 41,870 40,280 402 387 15 4
Daiichi Sankyo Savaysa Edoxaban Blood Disorders YEN Millions 1,484 1,908 14 18 -4 -22
Daiichi Sankyo Movantik Naloxegol Opioid-induced Constipation YEN Millions 3,498 4,664 34 45 -11 -25
Daiichi Sankyo Venofer Iron Sucrose Blood Disorders YEN Millions 27,348 29,468 263 283 -20 -7
Daiichi Sankyo Injectafer Ferric Carboxymaltose Blood Disorders YEN Millions 22,260 30,316 214 291 -77 -27
Daiichi Sankyo Total Revenues YEN Millions 549,398 582,532 5,274 5,592 -318 -6
Dainippon Sumitomo Aimix Amlodipine, Irbesartan Cardiovascular Diseases YEN Millions 19,300 17,300 185 166 19 12
Dainippon Sumitomo Trerief/Excegran Zonisamide Neurological/Mental Disorders YEN Millions 16,800 15,600 161 150 12 8
Dainippon Sumitomo Lonasen Blonanserin Neurological/Mental Disorders YEN Millions 13,400 13,600 129 131 -2 -1
Dainippon Sumitomo Metgluco Biguanide Diabetes YEN Millions 11,400 11,600 109 111 -2 -2
Dainippon Sumitomo Replagal Agalsidase Alfa Renal Disorders YEN Millions 11,900 10,900 114 105 10 9
Dainippon Sumitomo Trulicity Dulaglutide Diabetes YEN Millions 15,200 5,000 146 48 98 204
Dainippon Sumitomo Avapro Irbesartan Cardiovascular Diseases YEN Millions 10,200 10,800 98 104 -6 -6
Dainippon Sumitomo Surepost Repaglinide Diabetes YEN Millions 5,100 4,400 49 42 7 16
Dainippon Sumitomo Ambisome Amphotericin B Anti-fungal YEN Millions 4,500 4,500 43 43 0 0.0
Dainippon Sumitomo Amlodin Amlodipine Cardiovascular Diseases YEN Millions 12,200 13,800 117 132 -15 -12
Dainippon Sumitomo Prorenal Limaprost Alfadex Neurological/Mental Disorders YEN Millions 5,900 7,000 57 67 -11 -16
Dainippon Sumitomo Gasmotin Mosapride Citrate Gastrointestinal Disorders YEN Millions 5,400 6,500 52 62 -11 -17
Dainippon Sumitomo Meropen Meropenem Hydrate Anti-bacterial YEN Millions 30,200 26,900 290 258 32 12
Dainippon Sumitomo Latuda Lurasidone Neurological/Mental Disorders YEN Millions 349,000 255,770 3,350 2,455 895 36
Dainippon Sumitomo Brovana Arformoterol Respiratory Disorders YEN Millions 66,000 64,560 634 620 14 2
Dainippon Sumitomo Aptiom Eslicarbazepine Neurological/Mental Disorders YEN Millions 29,000 20,760 278 199 79 40
Dainippon Sumitomo Ciclesonide Ciclesonide Respiratory Disorders YEN Millions 5,000 10,590 48 102 -54 -53
Dainippon Sumitomo Xopenex Levalbuterol Respiratory Disorders YEN Millions 7,000 10,590 67 102 -34 -34
Dainippon Sumitomo New products for COPD YEN Millions 920 0 9 0 9 Not Available
Dainippon Sumitomo Total Sales YEN Millions 618,000 510,000 5,933 4,896 1,037 21
Eisai Co. Ltd. Humira Adalimumab Immunology (Organ Transplant, Arthritis etc.) YEN Millions 54,100 46,000 519 442 78 18
Eisai Co. Ltd. Lyrica Pregabalin Neurological/Mental Disorders YEN Millions 26,400 24,300 253 233 20 9
Eisai Co. Ltd. Aricept Donepezil Neurological/Mental Disorders YEN Millions 44,660 46,700 429 448 -20 -4
Eisai Co. Ltd. Pariet Rabeprazole Gastrointestinal Disorders YEN Millions 26,700 29,700 256 285 -29 -10
Eisai Co. Ltd. Methycobal Methylcobalamin Neurological/Mental Disorders YEN Millions 40,000 38,800 384 372 12 3
Eisai Co. Ltd. Lunesta Eszopiclone Neurological/Mental Disorders YEN Millions 9,900 7,500 95 72 23 32
Eisai Co. Ltd. Halaven Eribulin Oncology YEN Millions 39,600 38,600 380 371 10 3
Eisai Co. Ltd. Treakisym Bendamustine Oncology YEN Millions 6,500 4,200 62 40 22 55
Eisai Co. Ltd. Elental Branched-chain Amino Acid Preparation Nutritional Deficiency YEN Millions 6,600 New Launch 63 New Launch 63 New Launch
Eisai Co. Ltd. Warfarin Warfarin Cardiovascular Diseases YEN Millions 6,200 7,000 60 67 -8 -11
Eisai Co. Ltd. Livact Branched-chain Amino Acid Preparation Nutritional Deficiency YEN Millions 6,200 New Launch 60 New Launch 60 New Launch
Eisai Co. Ltd. Lenvima Lenvatinib Oncology YEN Millions 29,800 18,900 286 181 105 58
Eisai Co. Ltd. Fycompa Perampanel Neurological/Mental Disorders YEN Millions 13,400 9,600 129 92 36 40
Eisai Co. Ltd. Zebinix Eslicarbazepine Acetate Neurological/Mental Disorders YEN Millions 5,100 3,600 49 35 14 42
Eisai Co. Ltd. Zonegran Zonisamide Neurological/Mental Disorders YEN Millions 4,500 5,500 43 53 -10 -18
Eisai Co. Ltd. Inovelan Rufinamide Neurological/Mental Disorders YEN Millions 2,200 1,900 21 18 3 16
Eisai Co. Ltd. Stronger Neo-Minophagen C and Glycyron Glycyrrhizin preparation Gastrointestinal Disorders YEN Millions 9,900 8,500 95 82 13 16
Eisai Co. Ltd. Chocola BB Group Vitamin B2 YEN Millions 13,700 12,300 132 118 13 11
Eisai Co. Ltd. Aloxi Palonosetron Anti-emetic YEN Millions 44,800 48,400 430 465 -35 -7
Eisai Co. Ltd. Banzel Rufinamide Neurological/Mental Disorders YEN Millions 16,600 13,200 159 127 33 26
Eisai Co. Ltd. AcipHex Rabeprazole Gastrointestinal Disorders YEN Millions 6,500 7,100 62 68 -6 -8
Eisai Co. Ltd. Belviq Lorcaserin Weight Loss and Obesity YEN Millions 3,600 3,600 35 35 0 0.0
Eisai Co. Ltd. Actonel Risedronic Acid Bone and Joint Diseases YEN Millions Not Available 5,700 Not Available 55 -55 -101
Eisai Co. Ltd. Others YEN Millions 152,840 149,600 1,467 1,436 31 2
Eisai Co. Ltd. Total Revenue YEN Millions 569,800 530,700 5,470 5,095 375 7
Eli Lilly Zyprexa Olanzapine Neurological/Mental Disorders USD Millions 581 725 581 725 -144 -20
Eli Lilly Cymbalta Duloxetine Neurological/Mental Disorders USD Millions 757 931 757 931 -173 -19
Eli Lilly Strattera Atomoxetine Neurological/Mental Disorders USD Millions 618 855 618 855 -237 -28
Eli Lilly Other Neuroscience USD Millions 214 210 214 210 5 2
Eli Lilly Total Neuroscience USD Millions 2,171 2,720 2,171 2,720 -549 -20
Eli Lilly Taltz Ixekizumab Autoimmune Disorders USD Millions 559 113 559 113 446 394
Eli Lilly Other Immunology USD Millions 46 Not Available 46 Not Available 46 Not Available
Eli Lilly Total Immunology USD Millions 605 113 605 113 492 435
Eli Lilly Humalog Insulin Lispro Diabetes USD Millions 2,865 2,769 2,865 2,769 96 3
Eli Lilly Humulin Insulin Isophane Diabetes USD Millions 1,335 1,366 1,335 1,366 -31 -2
Eli Lilly Forteo Teriparatide Bone and Joint Diseases USD Millions 1,749 1,500 1,749 1,500 249 17
Eli Lilly Trajenta Linagliptin Diabetes USD Millions 538 437 538 437 101 23
Eli Lilly Jardiance Empagliflozin Diabetes USD Millions 448 202 448 202 246 122
Eli Lilly Trulicity Dulaglutide Diabetes USD Millions 2,030 926 2,030 926 1,104 119
Eli Lilly Basaglar Insulin Glargine Diabetes USD Millions 432 86 432 86 346 402
Eli Lilly Other Endocrinology USD Millions 688 798 688 798 -110 -14
Eli Lilly Total Endocrinology USD Millions 10,085 7,328 10,085 7,328 2,758 38
Eli Lilly Alimta Pemetrexed Oncology USD Millions 2,063 2,283 2,063 2,283 -221 -10
Eli Lilly Cyramza Ramucirumab Oncology USD Millions 758 614 758 614 144 23
Eli Lilly Erbitux Cetuximab Oncology USD Millions 646 687 646 687 -41 -6
Eli Lilly Other Oncology USD Millions 345 137 345 137 208 151
Eli Lilly Total Oncology USD Millions 3,812 3,584 3,812 3,584 228 6
Eli Lilly Cialis Tadalafil Sexual Health USD Millions 2,323 2,472 2,323 2,472 -149 -6
Eli Lilly Effient Prasugrel Cardiovascular Diseases USD Millions 389 535 389 535 -146 -27
Eli Lilly Other Cardiovascular USD Millions 159 219 159 219 -60 -27
Eli Lilly Total Cardiovascular USD Millions 2,871 3,057 2,871 3,057 -186 -6
Eli Lilly Other Human Pharmaceutical Products USD Millions 241 201 241 201 41 20
Eli Lilly Total Pharmaceuticals USD Millions 19,786 18,064 19,786 18,064 1,722 10
Eli Lilly Total Animal Health USD Millions 3,086 3,158 3,086 3,158 -73 -2
Eli Lilly Total Revenues USD Millions 22,871 21,222 22,871 21,222 1,649 8
Endo Pharmaceuticals Xiaflex Collagenase Clostridium Histolyticum Bone and Joint Diseases USD Millions 213 190 213 190 24 12
Endo Pharmaceuticals Supprelin LA Histrelin Acetate Oncology USD Millions 86 79 86 79 8 10
Endo Pharmaceuticals Other Specialty USD Millions 153 139 153 139 15 11
Endo Pharmaceuticals Total Specialty Products USD Millions 453 407 453 407 46 11
Endo Pharmaceuticals Opana ER Oxymorphone Hydrochloride Anti-inflammatory USD Millions 84 159 84 159 -75 -47
Endo Pharmaceuticals Percocet Oxycodone/Paracetamol Anti-inflammatory USD Millions 125 139 125 139 -14 -10
Endo Pharmaceuticals Voltaren Diclofenac Sodium Bone and Joint Diseases USD Millions 69 101 69 101 -32 -32
Endo Pharmaceuticals Lidoderm Lidocaine Anti-inflammatory USD Millions 52 88 52 88 -36 -41
Endo Pharmaceuticals Other Established USD Millions 175 273 175 273 -98 -36
Endo Pharmaceuticals Total Established Products USD Millions 505 759 505 759 -255 -34
Endo Pharmaceuticals Total U.S. Branded Pharmaceuticals USD Millions 958 1,166 958 1,166 -209 -18
Endo Pharmaceuticals U.S. Generics Base USD Millions 830 1,230 830 1,230 -400 -33
Endo Pharmaceuticals Sterile Injectables USD Millions 654 531 654 531 123 23
Endo Pharmaceuticals New Launches and Alternative Dosages USD Millions 797 804 797 804 -7 -1
Endo Pharmaceuticals Total U.S. Generic Pharmaceuticals USD Millions 2,281 2,565 2,281 2,565 -284 -11
Endo Pharmaceuticals Total International Pharmaceuticals USD Millions 230 279 230 279 -49 -18
Endo Pharmaceuticals Total Revenues USD Millions 3,469 4,010 3,469 4,010 -541 -14
Fresenius SE & Co. KGaA Fresenius Medical Care USD Millions 17,784 16,570 17,784 16,570 1,214 7
Fresenius SE & Co. KGaA Fresenius Kabi USD Millions 6,358 6,007 6,358 6,007 351 6
Fresenius SE & Co. KGaA Fresenius Helios USD Millions 8,668 5,843 8,668 5,843 2,825 48
Fresenius SE & Co. KGaA Fresenius Vamed USD Millions 1,228 1,160 1,228 1,160 68 6
Fresenius SE & Co. KGaA Total Revenues USD Millions 34,038 29,083 34,038 29,083 4,955 17
Gilead Sovaldi Sofosbuvir Infectious Diseases (HIV, Hepatitis etc.) USD Millions 964 4,001 964 4,001 -3,037 -76
Gilead Atripla Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Infectious Diseases (HIV, Hepatitis etc.) USD Millions 1,806 2,605 1,806 2,605 -799 -31
Gilead Truvada Emtricitabine, and Tenofovir Disoproxil Fumarate Infectious Diseases (HIV, Hepatitis etc.) USD Millions 3,134 3,566 3,134 3,566 -432 -12
Gilead Harvoni Ledipasvir and Sofosbuvir Infectious Diseases (HIV, Hepatitis etc.) USD Millions 4,370 9,081 4,370 9,081 -4,711 -52
Gilead Complera/Eviplera Rilpivirine, Emtricitabine, and Tenofovir Disoproxil Fumarate Infectious Diseases (HIV, Hepatitis etc.) USD Millions 966 1,457 966 1,457 -491 -34
Gilead Stribild Cobicistat, Elvitegravir, Emtricitabine and Tenofovir Disoproxil Fumarate Infectious Diseases (HIV, Hepatitis etc.) USD Millions 1,053 1,914 1,053 1,914 -861 -45
Gilead Viread Tenofovir Disoproxil Fumarate Infectious Diseases (HIV, Hepatitis etc.) USD Millions 1,046 1,186 1,046 1,186 -140 -12
Gilead Epclusa Sofosbuvir and Velpatasvir Infectious Diseases (HIV, Hepatitis etc.) USD Millions 3,510 1,752 3,510 1,752 1,758 100
Gilead Odefsey Emtricitabine, Rilpivirine, and Tenofovir Alafenamide Infectious Diseases (HIV, Hepatitis etc.) USD Millions 1,106 329 1,106 329 777 236
Gilead Descovy Emtricitabine and Tenofovir Alafenamide Infectious Diseases (HIV, Hepatitis etc.) USD Millions 1,218 298 1,218 298 920 309
Gilead Vosevi Sofosbuvir 400 mg/Velpatasvir 100 mg/Voxilaprevir 100 mg Infectious Diseases (HIV, Hepatitis etc.) USD Millions 293 New Launch 293 New Launch 293 New Launch
Gilead Genvoya Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide Infectious Diseases (HIV, Hepatitis etc.) USD Millions 3,674 1,484 3,674 1,484 2,190 148
Gilead Other Antiviral USD Millions 196 72 196 72 124 172
Gilead Total Antiviral Products USD Millions 23,336 27,745 23,336 27,745 -4,409 -16
Gilead Letairis Ambrisentan Cardiovascular Diseases USD Millions 887 819 887 819 68 8
Gilead Ranexa Ranolazine Cardiovascular Diseases USD Millions 717 677 717 677 40 6
Gilead AmBisome Amphotericin B Infectious Diseases (HIV, Hepatitis etc.) USD Millions 366 356 366 356 10 3
Gilead Zydelig Idelalisib Oncology USD Millions 149 168 149 168 -19 -11
Gilead Others USD Millions 207 188 207 188 19 10
Gilead Total Other Products USD Millions 2,326 2,208 2,326 2,208 118 5
Gilead Total Product Sales USD Millions 25,662 29,953 25,662 29,953 -4,291 -14
Gilead Royalty Contract and Other Revenues USD Millions 445 437 445 437 8 2
Gilead Total Revenues USD Millions 26,107 30,390 26,107 30,390 -4,283 -14
GlaxoSmithKline Anoro Ellipta Umeclidinium and Vilanterol Respiratory Disorders GBP Millions 342 201 482 283 199 70
GlaxoSmithKline Avamys/Veramyst Fluticasone Furoate  Respiratory Disorders GBP Millions 281 277 396 391 6 1
GlaxoSmithKline Flixotide/Flovent Fluticasone Propionate Respiratory Disorders GBP Millions 596 637 840 898 -58 -6
GlaxoSmithKline Relvar/Breo Ellipta Fluticasone Furoate  Respiratory Disorders GBP Millions 1,006 620 1,418 874 544 62
GlaxoSmithKline Seretide/Advair Salmeterol Respiratory Disorders GBP Millions 3,130 3,485 4,413 4,914 -501 -10
GlaxoSmithKline Incruse Ellipta Umeclidinium Respiratory Disorders GBP Millions 201 114 283 161 123 76
GlaxoSmithKline Nucala Mepolizumab Respiratory Disorders GBP Millions 344 102 485 144 341 237
GlaxoSmithKline Arnuity Ellipta Fluticasone Furoate Respiratory Disorders GBP Millions 35 15 49 21 28 133
GlaxoSmithKline Ventolin Albuterol Respiratory Disorders GBP Millions 767 785 1,081 1,107 -25 -2
GlaxoSmithKline Trelegy Ellipta Fluticasone Furoate, Vilanterol Trifenatate and Umeclidinium Bromide Respiratory Disorders GBP Millions 2 0 3 0 3 New Launch
GlaxoSmithKline Others GBP Millions 287 274 405 386 18 5
GlaxoSmithKline Total Respiratory GBP Millions 6,991 6,510 9,857 9,179 678 7
GlaxoSmithKline Benlysta Belimumab Rare Diseases GBP Millions 375 306 529 431 97 23
GlaxoSmithKline Others GBP Millions 2 34 3 48 -45 -94
GlaxoSmithKline Total Immuno-Inflammation GBP Millions 377 340 532 479 52 11
GlaxoSmithKline Epzicom/Kivexa Abacavir and Lamivudine Infectious Diseases (HIV, Hepatitis etc.) GBP Millions 234 568 330 801 -471 -59
GlaxoSmithKline Selzentry Maraviroc Infectious Diseases (HIV, Hepatitis etc.) GBP Millions 128 125 180 176 4 2
GlaxoSmithKline Tivicay Dolutegravir Infectious Diseases (HIV, Hepatitis etc.) GBP Millions 1,404 953 1,980 1,344 636 47
GlaxoSmithKline Triumeq Abacavir, Dolutegravir and Lamivudine Infectious Diseases (HIV, Hepatitis etc.) GBP Millions 2,461 1,735 3,470 2,446 1,024 42
GlaxoSmithKline Juluca Dolutegravir and Rilpivirine Infectious Diseases (HIV, Hepatitis etc.) GBP Millions 5 0 7 0 7 New Launch
GlaxoSmithKline Others GBP Millions 118 175 166 247 -80 -33
GlaxoSmithKline Total HIV GBP Millions 4,350 3,556 6,134 5,014 1,120 22
GlaxoSmithKline Dermatology GBP Millions 456 393 643 554 89 16
GlaxoSmithKline Augmentin Amoxicillin and Clavulanate Potassium Anti-bacterial GBP Millions 587 563 828 794 34 4
GlaxoSmithKline Avodart Dutasteride Urology GBP Millions 613 635 864 895 -31 -3
GlaxoSmithKline Eperzan/Tanzeum Albiglutide Diabetes GBP Millions 87 121 123 171 -48 -28
GlaxoSmithKline Coreg Carvedilol Cardiovascular Diseases GBP Millions 134 131 189 185 4 2
GlaxoSmithKline Imigran/Imitrex Sumatriptan Succinate Neurological/Mental Disorders GBP Millions 168 177 237 250 -13 -5
GlaxoSmithKline Lamictal Lamotrigine Neurological/Mental Disorders GBP Millions 650 614 917 866 51 6
GlaxoSmithKline Requip Ropinirole Neurological/Mental Disorders GBP Millions 110 116 155 164 -8 -5
GlaxoSmithKline Serevent Salmeterol Respiratory Disorders GBP Millions 96 96 135 135 0 0.0
GlaxoSmithKline Seroxat/Paxil Paroxetine Hydrochloride Hemihydrate Neurological/Mental Disorders GBP Millions 184 206 259 290 -31 -11
GlaxoSmithKline Valtrex Valacyclovir Infectious Diseases (HIV, Hepatitis etc.) GBP Millions 128 118 180 166 14 8
GlaxoSmithKline Zeffix Lamivudine Infectious Diseases (HIV, Hepatitis etc.) GBP Millions 89 111 125 157 -31 -20
GlaxoSmithKline Others GBP Millions 2,256 2,417 3,181 3,408 -227 -7
GlaxoSmithKline Established Products GBP Millions 5,558 5,698 7,837 8,034 -197 -2
GlaxoSmithKline Total Pharmaceuticals GBP Millions 17,276 16,104 24,359 22,707 1,653 7
GlaxoSmithKline Bexsero Meningococcal Vaccine Vaccine GBP Millions 556 390 784 550 234 43
GlaxoSmithKline Menveo Meningococcal Vaccine Vaccine GBP Millions 274 202 386 285 102 36
GlaxoSmithKline Other GBP Millions 60 70 85 99 -14 -14
GlaxoSmithKline Total Meningitis GBP Millions 890 662 1,255 933 321 34
GlaxoSmithKline Fluarix/FluLaval Influenza Vaccine Vaccine GBP Millions 488 414 688 584 104 18
GlaxoSmithKline Total Influenza GBP Millions 488 414 688 584 104 18
GlaxoSmithKline Shingrix Zoster Vaccine Recombinant, Adjuvanted Vaccine GBP Millions 22 0 31 0 31 New Launch
GlaxoSmithKline Total Shingles GBP Millions 22 New Launch 31 New Launch 31 New Launch
GlaxoSmithKline Boostrix Diphtheria, Tetanus Acellular, and Pertussis Vaccine GBP Millions 560 470 790 663 127 19
GlaxoSmithKline Cervarix Human Papillomavirus Bivalent Vaccine GBP Millions 134 81 189 114 75 65
GlaxoSmithKline Hepatitis Vaccine Vaccine GBP Millions 693 602 977 849 128 15
GlaxoSmithKline Infanrix/Pediarix Diphtheria, Tetanus Acellular, and Pertussis Vaccine GBP Millions 743 769 1,048 1,084 -37 -3
GlaxoSmithKline Rotarix Vaccine Vaccine GBP Millions 524 469 739 661 78 12
GlaxoSmithKline Priorix/Priorix Tetra/Varilrix Vaccine Vaccine GBP Millions 301 300 424 423 1 0.3
GlaxoSmithKline Synflorix Vaccine Vaccine GBP Millions 509 504 718 711 7 1
GlaxoSmithKline Others GBP Millions 296 321 417 453 -35 -8
GlaxoSmithKline Established Vaccines GBP Millions 3,760 3,516 5,302 4,958 344 7
GlaxoSmithKline Total Vaccines GBP Millions 5,160 4,592 7,276 6,475 801 12
GlaxoSmithKline Consumer Healthcare Turnover GBP Millions 7,750 7,193 10,928 10,142 785 8
GlaxoSmithKline Total Sales GBP Millions 30,186 27,889 42,562 39,323 3,239 8
Ipsen Decapeptyl Triptorelin Hormonal Disorders EURO Millions 349 340 432 421 11 3
Ipsen Somatuline Lanreotide Oncology EURO Millions 703 538 871 667 204 31
Ipsen Cabometyx Cabozantinib Oncology EURO Millions 52 7 64 9 55 618
Ipsen Onivyde Irinotecan Oncology EURO Millions 57 0 71 0 71 New Launch
Ipsen Other Oncology EURO Millions 25 20 31 24 7 30
Ipsen Oncology EURO Millions 1,185 905 1,470 1,122 348 31
Ipsen Dysport Abobotulinumtoxin A Lower Limb Spasticity EURO Millions 328 285 407 353 54 15
Ipsen Neuroscience EURO Millions 332 287 411 356 56 16
Ipsen NutropinAq Somatropin (rDNA origin) Growth Hormone EURO Millions 52 58 64 72 -7 -10
Ipsen Increlex Mecasermin Metabolic Disorders EURO Millions 23 24 28 29 -1 -3
Ipsen Rare Diseases EURO Millions 75 81 93 101 -8 -8
Ipsen Total Specialty Care EURO Millions 1,592 1,273 1,974 1,579 395 25
Ipsen Smecta Dioctahedral Smectite Gastrointestinal Disorders EURO Millions 116 111 143 138 6 4
Ipsen Fortrans/Eziclen Macrogol Gastrointestinal Disorders EURO Millions 32 27 40 33 7 20
Ipsen Etiasa Mesalazine Gastrointestinal Disorders EURO Millions 18 29 22 36 -14 -39
Ipsen Forlax Macrogol Gastrointestinal Disorders EURO Millions 42 39 52 49 3 7
Ipsen Tanakan Ginkgo Biloba Extract Neurological/Mental Disorders EURO Millions 41 44 51 54 -3 -5
Ipsen Other Consumer Healthcare EURO Millions 68 62 84 76 8 10
Ipsen Consumer Healthcare EURO Millions 317 312 393 386 6 2
Ipsen Group sales EURO Millions 1,909 1,585 2,367 1,965 402 20
Ipsen Other Revenues EURO Millions 103 87 128 107 20 19
Ipsen Total Sales EURO Millions 3,920 3,256 4,861 4,037 824 20
Johnson & Johnson Remicade Infliximab Autoimmune Disorders USD Millions 6,315 6,966 6,315 6,966 -651 -9
Johnson & Johnson Simponi/Simponi Aria Golimumab Immunology (Organ Transplant, Arthritis etc.) USD Millions 1,833 1,745 1,833 1,745 88 5
Johnson & Johnson Stelara Ustekinumab Immunology (Organ Transplant, Arthritis etc.) USD Millions 4,011 3,232 4,011 3,232 779 24
Johnson & Johnson Other Products USD Millions 85 25 85 25 60 240
Johnson & Johnson Total Immunology USD Millions 12,244 11,968 12,244 11,968 276 2
Johnson & Johnson Edurant Rilpivirine Infectious Diseases (HIV, Hepatitis etc.) USD Millions 714 573 714 573 141 25
Johnson & Johnson Prezista Darunavir Infectious Diseases (HIV, Hepatitis etc.) USD Millions 1,821 1,851 1,821 1,851 -30 -2
Johnson & Johnson Other Products USD Millions 619 784 619 784 -165 -21
Johnson & Johnson Total Infectious Diseases USD Millions 3,154 3,208 3,154 3,208 -54 -2
Johnson & Johnson Concerta Methylphenidate Neurological/Mental Disorders USD Millions 791 863 791 863 -72 -8
Johnson & Johnson Invega Sustenna/Xeplion/Trinza/Trevicta Paliperidone Palmitate Neurological/Mental Disorders USD Millions 2,569 2,214 2,569 2,214 355 16
Johnson & Johnson Risperdal Consta Risperidone Neurological/Mental Disorders USD Millions 805 893 805 893 -88 -10
Johnson & Johnson Other Products USD Millions 1,821 2,115 1,821 2,115 -294 -14
Johnson & Johnson Total Neuroscience USD Millions 5,986 6,085 5,986 6,085 -99 -2
Johnson & Johnson Darzalex Daratumumab Oncology USD Millions 1,242 572 1,242 572 670 117
Johnson & Johnson Imbruvica Ibrutinib Oncology USD Millions 1,893 1,251 1,893 1,251 642 51
Johnson & Johnson Velcade Bortezomib Oncology USD Millions 1,114 1,224 1,114 1,224 -110 -9
Johnson & Johnson Zytiga Abiraterone Acetate Oncology USD Millions 2,505 2,260 2,505 2,260 245 11
Johnson & Johnson Other Products USD Millions 504 500 504 500 4 1
Johnson & Johnson Total Oncology USD Millions 7,258 5,807 7,258 5,807 1,451 25
Johnson & Johnson Invokana/Invokamet Canagliflozin/ Canagliflozin and Metformin HCl Diabetes USD Millions 1,111 1,407 1,111 1,407 -296 -21
Johnson & Johnson Procrit/Eprex Epoetin Alfa Blood Disorders USD Millions 972 1,105 972 1,105 -133 -12
Johnson & Johnson Xarelto Rivaroxaban Cardiovascular Diseases USD Millions 2,500 2,288 2,500 2,288 212 9
Johnson & Johnson Other Products USD Millions 1,704 1,596 1,704 1,596 108 7
Johnson & Johnson Total Cardiovascular/Metabolic Disorders/Other USD Millions 6,287 6,396 6,287 6,396 -109 -2
Johnson & Johnson Opsumit Macitentan Cardiovascular Diseases USD Millions 573 878 573 878 -305 -35
Johnson & Johnson Tracleer Bosentan Cardiovascular Diseases USD Millions 403 1,078 403 1,078 -675 -63
Johnson & Johnson Uptravi Selexipag Cardiovascular Diseases USD Millions 263 259 263 259 4 2
Johnson & Johnson Other Products USD Millions 88 335 88 335 -247 -74
Johnson & Johnson Total Pulmonary Hypertension USD Millions 1,327 Actelion products acquired by J & J 1,327 Actelion products acquired by J & J 1,327 Actelion products acquired by J & J
Johnson & Johnson Total Pharmaceuticals USD Millions 36,256 33,464 36,256 33,464 2,792 8
Johnson & Johnson Consumer HealthCare USD Millions 13,602 13,307 13,602 13,307 295 2
Johnson & Johnson Medical Devices USD Millions 26,592 25,119 26,592 25,119 1,473 6
Johnson & Johnson Total All Divisions USD Millions 76,450 71,890 76,450 71,890 4,560 6
Kyowa Kirin Nesp Darbepoetin Alfa Renal Disorders YEN Millions 62,000 61,300 595 588 7 1
Kyowa Kirin Espo Epoetin Alfa Renal Disorders YEN Millions 1,400 1,600 13 15 -2 -13
Kyowa Kirin Regpara Cinacalcet Hydrochloride Hormonal Disorders YEN Millions 20,700 21,800 199 209 -11 -5
Kyowa Kirin Rocaltrol Calcitriol Hormonal Disorders YEN Millions 4,100 4,200 39 40 -1 -2
Kyowa Kirin Onglyza Saxagliptin Diabetes YEN Millions 7,300 6,300 70 60 10 16
Kyowa Kirin Coniel Benidipine Cardiovascular Diseases YEN Millions 6,300 7,600 60 73 -12 -17
Kyowa Kirin G-Lasta Pegfilgrastim Blood Disorders YEN Millions 18,100 15,500 174 149 25 17
Kyowa Kirin Gran Filgrastim Blood Disorders YEN Millions 8,500 9,000 82 86 -5 -6
Kyowa Kirin Fentos Fentanyl Transdermal Persistent Pain YEN Millions 6,000 6,300 58 60 -3 -5
Kyowa Kirin Poteligeo Mogamulizumab Oncology YEN Millions 1,900 1,900 18 18 0 0.0
Kyowa Kirin Romiplate Romiplostim Blood Disorders YEN Millions 3,400 3,300 33 32 1 3
Kyowa Kirin Allelock Olopatadine Hydrochloride Anti-allergic YEN Millions 15,900 18,200 153 175 -22 -13
Kyowa Kirin Patanol Olopatadine Hydrochloride Anti-allergic YEN Millions 12,800 13,000 123 125 -2 -2
Kyowa Kirin Asacol Mesalazine Gastrointestinal Disorders YEN Millions 4,200 4,800 40 46 -6 -13
Kyowa Kirin Dovobet Calcipotriol Hydrate + Betamethasone Dipropionate Dermatology YEN Millions 5,300 5,500 51 53 -2 -4
Kyowa Kirin Lumicef Brodalumab Dermatology YEN Millions 1,000 100 10 1 9 900
Kyowa Kirin Nouriast Istradefylline Neurological/Mental Disorders YEN Millions 8,500 7,300 82 70 12 16
Kyowa Kirin Depakene Sodium Valproate Neurological/Mental Disorders YEN Millions 6,500 7,300 62 70 -8 -11
Kyowa Kirin Nauzelin Domperidone Gastrointestinal Disorders YEN Millions 2,500 3,200 24 31 -7 -22
Kyowa Kirin Neulasta/Peglasta Pegfilgrastim Blood Disorders YEN Millions 2,000 1,500 19 14 5 33
Kyowa Kirin Abstral Fentanyl Sublingual Oncology YEN Millions 11,900 10,600 114 102 12 12
Kyowa Kirin PecFent Fentanyl Intranasal Spray Oncology YEN Millions 4,100 4,000 39 38 1 3
Kyowa Kirin Mitomycin-C Mitomycin Oncology YEN Millions 3,400 3,200 33 31 2 6
Kyowa Kirin Sancuso Granisetron Transdermal System Anti-emetic YEN Millions 3,000 3,100 29 30 -1 -3
Kyowa Kirin Moventig Naloxegol Opioid-induced Constipation YEN Millions 800 300 8 3 5 167
Kyowa Kirin Tostran/Fortesta Testosterone Topical Tostrex Hormonal Disorders YEN Millions 2,200 2,400 21 23 -2 -8
Kyowa Kirin Rectogesic Nitroglycerin Topical Urology YEN Millions 1,600 1,700 15 16 -1 -6
Kyowa Kirin Adcal-D3 Calcium Carbonate, Cholecalciferol Bone and Joint Diseases YEN Millions 3,600 3,900 35 37 -3 -8
Kyowa Kirin Technology out-licensing YEN Millions 18,400 12,700 177 122 55 45
Kyowa Kirin Total Pharmaceuticals YEN Millions 247,400 241,600 2,375 2,319 56 2
Kyowa Kirin Others YEN Millions 106,000 106,400 1,018 1,021 -4 -0.4
Kyowa Kirin Total Revenues YEN Millions 353,400 348,000 3,393 3,341 52 2
Lundbeck Abilify Maintena Aripiprazole Neurological/Mental Disorders DKK Millions 1,331 1,114 226 189 37 19
Lundbeck Brintellix/Trintellix Vortioxetine Neurological/Mental Disorders DKK Millions 1,662 1,105 283 188 95 50
Lundbeck Cipralex/Lexapro Escitalopram Neurological/Mental Disorders DKK Millions 2,369 2,518 403 428 -25 -6
Lundbeck Northera Droxidopa Neurological/Mental Disorders DKK Millions 1,644 1,087 279 185 95 51
Lundbeck Onfi Clobazam Neurological/Mental Disorders DKK Millions 3,022 2,409 514 410 104 25
Lundbeck Rexulti Brexpiprazole Neurological/Mental Disorders DKK Millions 1,247 826 212 140 72 51
Lundbeck Sabril Vigabatrin Neurological/Mental Disorders DKK Millions 1,509 1,342 257 228 28 12
Lundbeck Xenazine Tetrabenazine Neurological/Mental Disorders DKK Millions 1,049 1,571 178 267 -89 -33
Lundbeck Ebixa Memantine Hydrochloride Neurological/Mental Disorders DKK Millions 460 487 78 83 -5 -6
Lundbeck Other Pharmaceuticals DKK Millions 2,542 2,850 432 485 -52 -11
Lundbeck Other Revenues DKK Millions 399 325 68 55 13 23
Lundbeck Total Revenues DKK Millions 17,234 15,634 2,930 2,658 272 10
Mallinckrodt Plc Acthar Corticotropin Autoimmune Disorders USD Millions 1,195 1,486 1,195 1,486 -291 -20
Mallinckrodt Plc Inomax Nitric Oxide Respiratory Disorders USD Millions 505 593 505 593 -88 -15
Mallinckrodt Plc Ofirmev Acetaminophen Anti-inflammatory USD Millions 303 357 303 357 -54 -15
Mallinckrodt Plc Therakos Immunotherapy USD Millions 215 255 215 255 -40 -16
Mallinckrodt Plc Hemostasis products USD Millions 55 56 55 56 -1 -2
Mallinckrodt Plc Others USD Millions 53 158 53 158 -105 -66
Mallinckrodt Plc Specialty Brands USD Millions 2,326 2,904 2,326 2,904 -578 -20
Mallinckrodt Plc Hydrocodone (API) and Hydrocodone-containing tablets Hydrocodone Bitartrate Anti-inflammatory USD Millions 85 170 85 170 -85 -50
Mallinckrodt Plc Oxycodone (API) and Oxycodone-containing Tablets Oxycodone Anti-inflammatory USD Millions 79 151 79 151 -72 -48
Mallinckrodt Plc Methylphenidate ER Methylphenidate Hydrochloride Neurological/Mental Disorders USD Millions 72 126 72 126 -54 -43
Mallinckrodt Plc Other Controlled Substances USD Millions 410 573 410 573 -163 -28
Mallinckrodt Plc Others USD Millions 194 219 194 219 -25 -12
Mallinckrodt Plc Specialty Generics USD Millions 840 1,025 840 1,025 -185 -18
Mallinckrodt Plc Others USD Millions 57 69 57 69 -12 -17
Mallinckrodt Plc Total Sales USD Millions 3,222 4,211 3,222 4,211 -989 -23
Merck & Co. Inc. Zetia Ezetimibe Cardiovascular Diseases USD Millions 1,344 2,560 1,344 2,560 -1,216 -48
Merck & Co. Inc. Vytorin Ezetimibe and Simvastatin Cardiovascular Diseases USD Millions 751 1,141 751 1,141 -390 -34
Merck & Co. Inc. Atozet Ezetimibe and Atorvastatin Cardiovascular Diseases USD Millions 225 147 225 147 78 53
Merck & Co. Inc. Adempas Riociguat Cardiovascular Diseases USD Millions 300 169 300 169 131 78
Merck & Co. Inc. Total Cardiovascular USD Millions 2,620 3,848 2,620 3,848 -1,228 -32
Merck & Co. Inc. Januvia Sitagliptin Diabetes USD Millions 3,737 3,908 3,737 3,908 -171 -4
Merck & Co. Inc. Janumet Metformin and Sitagliptin Diabetes USD Millions 2,158 2,201 2,158 2,201 -43 -2
Merck & Co. Inc. Total Diabetes USD Millions 5,895 6,109 5,895 6,109 -214 -4
Merck & Co. Inc. NuvaRing Ethinyl Estradiol and Etonogestrel Sexual Health USD Millions 761 777 761 777 -16 -2
Merck & Co. Inc. Implanon/Nexplanon Etonogestrel Sexual Health USD Millions 686 606 686 606 80 13
Merck & Co. Inc. Follistim AQ Follicle Stimulating Hormone Sexual Health USD Millions 298 355 298 355 -57 -16
Merck & Co. Inc. Total General Medicine & Women’s Health USD Millions 1,745 1,738 1,745 1,738 7 0.4
Merck & Co. Inc. Zepatier Elbasvir and Grazoprevir Infectious Diseases (HIV, Hepatitis etc.) USD Millions 1,660 555 1,660 555 1,105 199
Merck & Co. Inc. Total Hepatitis USD Millions 1,660 555 1,660 555 1,105 199
Merck & Co. Inc. Isentress Raltegravir Infectious Diseases (HIV, Hepatitis etc.) USD Millions 1,204 1,387 1,204 1,387 -183 -13
Merck & Co. Inc. Total HIV USD Millions 1,204 1,387 1,204 1,387 -183 -13
Merck & Co. Inc. Cubicin Daptomycin Anti-bacterial USD Millions 382 1,087 382 1,087 -705 -65
Merck & Co. Inc. Cancidas Caspofungin Anti-fungal USD Millions 422 558 422 558 -136 -24
Merck & Co. Inc. Invanz Ertapenem Anti-bacterial USD Millions 602 561 602 561 41 7
Merck & Co. Inc. Noxafil Posaconazole Anti-fungal USD Millions 636 595 636 595 41 7
Merck & Co. Inc. Bridion Sugammadex Neurological/Mental Disorders USD Millions 704 482 704 482 222 46
Merck & Co. Inc. Primaxin Imipenem and Cilastatin Anti-bacterial USD Millions 280 297 280 297 -17 -6
Merck & Co. Inc. Total Hospital Acute Care USD Millions 3,026 3,580 3,026 3,580 -554 -15
Merck & Co. Inc. Remicade Infliximab Autoimmune Disorders USD Millions 837 1,268 837 1,268 -431 -34
Merck & Co. Inc. Simponi Golimumab Immunology (Organ Transplant, Arthritis etc.) USD Millions 819 766 819 766 53 7
Merck & Co. Inc. Total Immunology USD Millions 1,656 2,034 1,656 2,034 -378 -19
Merck & Co. Inc. Keytruda Pembrolizumab Oncology USD Millions 3,809 1,402 3,809 1,402 2,407 172
Merck & Co. Inc. Emend Aprepitant Oncology USD Millions 556 549 556 549 7 1
Merck & Co. Inc. Temodar Temozolamide Others USD Millions 271 283 271 283 -12 -4
Merck & Co. Inc. Total Oncology USD Millions 4,636 2,234 4,636 2,234 2,402 108
Merck & Co. Inc. Singulair Montelukast Sodium Respiratory Disorders USD Millions 732 915 732 915 -183 -20
Merck & Co. Inc. Nasonex Mometasone Furoate Respiratory Disorders USD Millions 387 537 387 537 -150 -28
Merck & Co. Inc. Dulera Formoterol and Mometasone Respiratory Disorders USD Millions 287 436 287 436 -149 -34
Merck & Co. Inc. Total Respiratory USD Millions 1,406 1,888 1,406 1,888 -482 -26
Merck & Co. Inc. Cozaar/Hyzaar Losartan and Hydrochlorothiazide Cardiovascular Diseases USD Millions 484 511 484 511 -27 -5
Merck & Co. Inc. Arcoxia Etoricoxib Immunology (Organ Transplant, Arthritis etc.) USD Millions 363 450 363 450 -87 -19
Merck & Co. Inc. Fosamax Alendronate Bone and Joint Diseases USD Millions 241 284 241 284 -43 -15
Merck & Co. Inc. Total Other USD Millions 1,088 1,245 1,088 1,245 -157 -13
Merck & Co. Inc. Gardasil/Gardasil 9 HPV Quadrivalent Vaccine Oncology USD Millions 2,308 2,173 2,308 2,173 135 6
Merck & Co. Inc. ProQuad, M-M-R II and Varivax Measles, Mumps, Rubella and Varicella Virus Vaccine Live Infectious Diseases (HIV, Hepatitis etc.) USD Millions 1,676 1,640 1,676 1,640 36 2
Merck & Co. Inc. Zostavax Zoster Vaccine Live Infectious Diseases (HIV, Hepatitis etc.) USD Millions 668 685 668 685 -17 -2
Merck & Co. Inc. RotaTeq Rotavirus Vaccine Infectious Diseases (HIV, Hepatitis etc.) USD Millions 686 652 686 652 34 5
Merck & Co. Inc. Pneumovax 23 Pneumococcal Vaccine Polyvalent Infectious Diseases (HIV, Hepatitis etc.) USD Millions 821 641 821 641 180 28
Merck & Co. Inc. Total Vaccines USD Millions 6,159 5,791 6,159 5,791 368 6
Merck & Co. Inc. Other Pharmaceutical USD Millions 4,295 4,574 4,295 4,574 -279 -6
Merck & Co. Inc. Total Pharmaceuticals USD Millions 35,390 35,150 35,390 35,150 240 1
Merck & Co. Inc. Other Segment Sales USD Millions 4,272 3,862 4,272 3,862 410 11
Merck & Co. Inc. Total Segment Sales USD Millions 39,662 39,013 39,662 39,013 649 2
Merck & Co. Inc. Other Revenues USD Millions 460 794 460 794 -334 -42
Merck & Co. Inc. Total Sales USD Millions 40,122 39,807 40,122 39,807 315 1
Mitsubishi Tanabe Domestic Ethical Drugs YEN Millions 320,400 310,600 3,076 2,982 94 3
Mitsubishi Tanabe Remicade Infliximab Autoimmune Disorders YEN Millions 65,800 67,400 632 647 -15 -2
Mitsubishi Tanabe Simponi Golimumab Rheumatoid Arthritis YEN Millions 30,200 22,200 290 213 77 36
Mitsubishi Tanabe Tenelia Teneligliptin Diabetes YEN Millions 18,500 16,400 178 157 20 13
Mitsubishi Tanabe Talion Bepotastine Anti-allergic YEN Millions 18,900 18,400 181 177 5 3
Mitsubishi Tanabe Lexapro Escitalopram Oxalate Neurological/Mental Disorders YEN Millions 12,400 10,700 119 103 16 16
Mitsubishi Tanabe Ceredist Taltirelin Hormonal Disorders YEN Millions 11,200 12,500 108 120 -12 -10
Mitsubishi Tanabe Maintate Bisoprolol Cardiovascular Diseases YEN Millions 11,000 12,100 106 116 -11 -9
Mitsubishi Tanabe Kremezin Spherical Carbon Adsorbent Renal Disorders YEN Millions 6,600 7,800 63 75 -12 -15
Mitsubishi Tanabe Depas Etizolam Neurological/Mental Disorders YEN Millions 1,200 6,200 12 60 -48 -81
Mitsubishi Tanabe Radicut Edaravone Neurological/Mental Disorders YEN Millions 5,600 6,200 54 60 -6 -10
Mitsubishi Tanabe Canaglu Canagliflozin Diabetes YEN Millions 5,200 2,500 50 24 26 108
Mitsubishi Tanabe Urso Ursodiol Gastrointestinal Disorders YEN Millions 5,400 6,300 52 60 -9 -14
Mitsubishi Tanabe Imusera Fingolimod Hydrochloride Neurological/Mental Disorders YEN Millions 4,700 3,800 45 36 9 24
Mitsubishi Tanabe BIKEN Products [Vaccines] YEN Millions 37,700 38,600 362 371 -9 -2
Mitsubishi Tanabe Influenza Vaccine Anti-viral YEN Millions 11,800 12,700 113 122 -9 -7
Mitsubishi Tanabe Tetrabik Diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain) Anti-viral YEN Millions 8,900 9,800 85 94 -9 -9
Mitsubishi Tanabe Mearubik Anti-viral YEN Millions 5,500 5,500 53 53 0 0.0
Mitsubishi Tanabe Varicella Vaccine Anti-viral YEN Millions 5,200 5,400 50 52 -2 -4
Mitsubishi Tanabe Tanabe Seiyaku Hanbai Products YEN Millions 9,900 14,000 95 134 -39 -29
Mitsubishi Tanabe Overseas Ethical Drugs YEN Millions 32,200 21,500 309 206 103 50
Mitsubishi Tanabe Radicava Edaravone Neurological/Mental Disorders YEN Millions 6,400 0 61 0 61 New Launch
Mitsubishi Tanabe Herbesser Diltiazem Cardiovascular Diseases YEN Millions 6,300 6,100 60 59 2 3
Mitsubishi Tanabe Novastan Argatroban Blood Disorders YEN Millions 2,000 2,000 19 19 0 0.0
Mitsubishi Tanabe Simponi Golimumab Rheumatoid Arthritis YEN Millions 1,800 1,300 17 12 5 38
Mitsubishi Tanabe Tanatril Imidapril Cardiovascular Diseases YEN Millions 1,500 1,500 14 14 0 0.0
Mitsubishi Tanabe Royalty Revenues, etc. YEN Millions 81,100 77,500 779 744 35 5
Mitsubishi Tanabe Royalty from Gilenya Fingolimod Neurological/Mental Disorders YEN Millions 56,400 53,700 541 516 26 5
Mitsubishi Tanabe Royalty from Invokana Canagliflozin Diabetes YEN Millions 14,600 19,200 140 184 -44 -24
Mitsubishi Tanabe OTC Products YEN Millions 3,600 3,500 35 34 1 3
Mitsubishi Tanabe Others YEN Millions 1,300 1,900 12 18 -6 -32
Mitsubishi Tanabe Total Sales Revenues YEN Millions 438,900 415,500 4,213 3,989 225 6
Mylan Central Nervous System and Anesthesia USD Millions 2,238 2,030 2,238 2,030 208 10
Mylan Respiratory and Allergy USD Millions 1,383 1,813 1,383 1,813 -431 -24
Mylan Infectious Disease USD Millions 1,463 1,303 1,463 1,303 160 12
Mylan Cardiovascular USD Millions 1,220 1,165 1,220 1,165 54 5
Mylan Gastroenterology USD Millions 1,115 1,029 1,115 1,029 85 8
Mylan Diabetes and Metabolism USD Millions 947 972 947 972 -25 -3
Mylan Oncology USD Millions 701 764 701 764 -64 -8
Mylan Women’s Healthcare USD Millions 712 594 712 594 118 20
Mylan Dermatology USD Millions 911 370 911 370 542 147
Mylan Immunology USD Millions 145 133 145 133 12 9
Mylan Other USD Millions 926 794 926 794 133 17
Mylan Net Sales USD Millions 11,760 10,967 11,760 10,967 793 7
Mylan Other Revenues USD Millions 148 110 148 110 38 35
Mylan Total Revenues USD Millions 11,908 11,077 11,908 11,077 831 8
Novartis Gleevec/Glivec Imatinib Oncology USD Millions 1,943 3,323 1,943 3,323 -1,380 -42
Novartis Tasigna Nilotinib Oncology USD Millions 1,841 1,739 1,841 1,739 102 6
Novartis Subtotal Bcr-Abl Franchise USD Millions 3,784 5,062 3,784 5,062 -1,278 -25
Novartis Sandostatin Octreotide Oncology USD Millions 1,612 1,646 1,612 1,646 -34 -2
Novartis Afinitor/Votubia Everolimus Oncology USD Millions 1,525 1,516 1,525 1,516 9 1
Novartis Exjade/Jadenu Deferasirox Oncology USD Millions 1,059 956 1,059 956 103 11
Novartis Votrient Pazopanib Oncology USD Millions 808 729 808 729 79 11
Novartis Tafinlar/Mekinist Dabrafenib/Trametinib Oncology USD Millions 873 672 873 672 201 30
Novartis Jakavi Ruxolitinib Oncology USD Millions 777 581 777 581 196 34
Novartis Revolade/Promacta Eltrombopag Olamine/Eltrombopag Oncology USD Millions 867 635 867 635 232 37
Novartis Kisqali Ribociclib Oncology USD Millions 76 0 76 0 76 New Launch
Novartis Others USD Millions 893 993 893 993 -100 -10
Novartis Total Oncology USD Millions 12,274 12,790 12,274 12,790 -516 -4
Novartis Gilenya Fingolimod Neurological/Mental Disorders USD Millions 3,185 3,109 3,185 3,109 76 2
Novartis Others USD Millions 102 124 102 124 -22 -18
Novartis Total Neuroscience USD Millions 3,287 3,233 3,287 3,233 54 2
Novartis Lucentis Ranibizumab Ophthalmology USD Millions 1,888 1,835 1,888 1,835 53 3
Novartis Travoprost Group Travoprost Ophthalmology USD Millions 589 619 589 619 -30 -5
Novartis Topical Olopatadine Group Olopatadine Ophthalmology USD Millions 284 335 284 335 -51 -15
Novartis Systane Group Propylene Glycol Ophthalmology USD Millions 400 377 400 377 23 6
Novartis Other USD Millions 2,207 2,297 2,207 2,297 -90 -4
Novartis Total Ophthalmology USD Millions 5,368 5,463 5,368 5,463 -95 -2
Novartis Neoral/Sandimmun(e) Cyclosporine Immunology (Organ Transplant, Arthritis etc.) USD Millions 488 515 488 515 -27 -5
Novartis Myfortic Mycophenolic Acid Immunology (Organ Transplant, Arthritis etc.) USD Millions 378 383 378 383 -5 -1
Novartis Zortress/Certican Everolimus Immunology (Organ Transplant, Arthritis etc.) USD Millions 414 398 414 398 16 4
Novartis Cosentyx Secukinumab Immunology (Organ Transplant, Arthritis etc.) USD Millions 2,071 1,128 2,071 1,128 943 84
Novartis Ilaris Canakinumab Rare Diseases USD Millions 402 283 402 283 119 42
Novartis Others USD Millions 288 308 288 308 -20 -6
Novartis Total Immunology and Dermatology USD Millions 4,041 3,015 4,041 3,015 1,026 34
Novartis Ultibro Breezhaler Indacaterol and Glycopyrronium Bromide Respiratory Disorders USD Millions 411 363 411 363 48 13
Novartis Onbrez Breezhaler/Arcapta Neohaler Indacaterol Maleate Respiratory Disorders USD Millions 112 143 112 143 -31 -22
Novartis Seebri Breezhaler Glycopyrronium Bromide Respiratory Disorders USD Millions 151 149 151 149 2 1
Novartis Subtotal COPD1 portfolio USD Millions 674 655 674 655 19 3
Novartis Xolair Omalizumab Respiratory Disorders USD Millions 920 835 920 835 85 10
Novartis Others USD Millions 23 31 23 31 -8 -26
Novartis Total Respiratory USD Millions 1,617 1,521 1,617 1,521 96 6
Novartis Entresto Sacubitril and Valsartan Cardiovascular Diseases USD Millions 507 170 507 170 337 198
Novartis Others USD Millions 17 14 17 14 3 21
Novartis Total Cardio-Metabolic USD Millions 524 184 524 184 340 185
Novartis Exelon/Exelon Patch Rivastigmine Neurological/Mental Disorders USD Millions 381 444 381 444 -63 -14
Novartis Galvus Vildagliptin Diabetes USD Millions 1,233 1,193 1,233 1,193 40 3
Novartis Diovan/Co-Diovan Hydrochlorothiazide and Valsartan Cardiovascular Diseases USD Millions 957 1,073 957 1,073 -116 -11
Novartis Exforge Amlodipine and Valsartan Cardiovascular Diseases USD Millions 960 926 960 926 34 4
Novartis Voltaren/Cataflam Diclofenac Anti-inflammatory USD Millions 465 525 465 525 -60 -11
Novartis Ritalin/Focalin Dexmethylphenidate Neurological/Mental Disorders USD Millions 236 282 236 282 -46 -16
Novartis Others USD Millions 1,682 1,913 1,682 1,913 -231 -12
Novartis Total Established Medicines USD Millions 5,914 6,356 5,914 6,356 -442 -7
Novartis Total PharmaceuticalnBusiness Unit USD Millions 20,751 19,772 20,751 19,772 979 5
Novartis Total Division Net Sales USD Millions 33,025 32,562 33,025 32,562 463 1
Novartis Net Sales by Alcon USD Millions 6,024 5,812 6,024 5,812 212 4
Novartis Net Sales by Sandoz USD Millions 10,060 10,144 10,060 10,144 -84 -1
Novartis Total Group Net Sales USD Millions 49,109 48,518 49,109 48,518 591 1
Novo Nordisk Tresiba Insulin Degludec Diabetes DKK Millions 7,327 4,056 1,246 690 556 81
Novo Nordisk New-generation Insulin DKK Millions 8,647 4,459 1,470 758 712 94
Novo Nordisk NovoRapid/NovoLog Insulin Aspart Diabetes DKK Millions 20,025 19,945 3,404 3,391 14 0.4
Novo Nordisk NovoMix/NovoLog Mix Biphasic Insulin Aspart Diabetes DKK Millions 10,257 10,482 1,744 1,782 -38 -2
Novo Nordisk Levemir Insulin Detemir Diabetes DKK Millions 14,118 17,083 2,400 2,904 -504 -17
Novo Nordisk Total Modern Insulins DKK Millions 44,400 47,510 7,548 8,077 -529 -7
Novo Nordisk Human Insulins Insulin Diabetes DKK Millions 10,072 11,090 1,712 1,885 -173 -9
Novo Nordisk Total Insulin DKK Millions 63,119 63,059 10,730 10,720 10 0.1
Novo Nordisk Victoza Liraglutide Diabetes DKK Millions 23,173 20,046 3,939 3,408 532 16
Novo Nordisk Other Diabetes Care DKK Millions 4,023 4,267 684 725 -41 -6
Novo Nordisk of which Saxenda Liraglutide Weight Loss and Obesity DKK Millions 2,562 1,577 436 268 167 62
Novo Nordisk Total Diabetes Care DKK Millions 92,877 88,949 15,789 15,121 668 4
Novo Nordisk Haemophilia Recombinant Human Coagulation Factor VIIa Blood Disorders DKK Millions 10,469 10,472 1,780 1,780 -1 0.0
Novo Nordisk Growth Disorders DKK Millions 6,655 8,770 1,131 1,491 -360 -24
Novo Nordisk Other Biopharmaceuticals DKK Millions 1,695 3,589 288 610 -322 -53
Novo Nordisk Total Biopharmaceuticals DKK Millions 18,819 22,831 3,199 3,881 -682 -18
Novo Nordisk Total Sales DKK Millions 111,696 111,780 18,988 19,003 -14 -0.1
Ono Pharmaceuticals Opdivo Nivolumab Oncology YEN Millions 90,300 98,100 867 942 -75 -8
Ono Pharmaceuticals Emend/Proemend Aprepitant Oncology YEN Millions 10,100 9,800 97 94 3 3
Ono Pharmaceuticals Glactiv Sitagliptin Phosphate Hydrate Diabetes YEN Millions 29,000 28,800 278 276 2 1
Ono Pharmaceuticals Forxiga Dapagliflozin Diabetes YEN Millions 10,500 7,100 101 68 33 48
Ono Pharmaceuticals Kinedak Epalrestat Diabetes YEN Millions 2,400 3,100 23 30 -7 -23
Ono Pharmaceuticals Recalbon Minodronic Acid Bone and Joint Diseases YEN Millions 11,100 11,200 107 108 -1 -1
Ono Pharmaceuticals Orencia SC Abatacept Rheumatoid Arthritis YEN Millions 13,800 10,700 132 103 30 29
Ono Pharmaceuticals Rivastach Rivastigmine Neurological/Mental Disorders YEN Millions 9,100 8,500 87 82 6 7
Ono Pharmaceuticals Staybla Imidafenacin Renal Disorders YEN Millions 4,400 4,900 42 47 -5 -10
Ono Pharmaceuticals Opalmon Limaprost Alfadex Cardiovascular Diseases YEN Millions 15,200 18,000 146 173 -27 -16
Ono Pharmaceuticals Onon Pranlukast Respiratory Disorders YEN Millions 9,500 11,700 91 112 -21 -19
Ono Pharmaceuticals Onoact Landiolol Cardiovascular Diseases YEN Millions 5,900 5,500 57 53 4 7
Ono Pharmaceuticals Foipan Camostat Mesilate Gastrointestinal Disorders YEN Millions 3,200 4,000 31 38 -8 -20
Ono Pharmaceuticals Parsabiv Etelcalcetide Hormonal Disorders YEN Millions 4,500 0 43 Not Available 43 Not Available
Ono Pharmaceuticals Kyprolis Carfilzomib Oncology YEN Millions 5,400 New Launch 52 Not Available 52 Not Available
Ono Pharmaceuticals Elaspol Sivelestat Respiratory Disorders YEN Millions 0 300 0 3 -3 -100
Ono Pharmaceuticals Others YEN Millions 32,200 15,300 309 147 162 110
Ono Pharmaceuticals Total Revenues YEN Millions 256,600 237,000 2,463 2,275 188 8
Otsuka Abilify Aripiprazole Neurological/Mental Disorders YEN Millions 67,300 95,400 646 916 -270 -29
Otsuka Abilify Maintena Aripiprazole Neurological/Mental Disorders YEN Millions 70,900 57,200 681 549 132 24
Otsuka Rexulti Brexpiprazole Neurological/Mental Disorders YEN Millions 47,300 29,800 454 286 168 59
Otsuka Nuedexta Dextromethorphan and Quinidine Neurological/Mental Disorders YEN Millions 25,600 23,600 246 227 19 8
Otsuka Pletaal/Pletal Cilostazol Cardiovascular Diseases YEN Millions 20,900 23,600 201 227 -26 -11
Otsuka Mucosta Rebamipide Gastrointestinal Disorders YEN Millions 11,400 12,500 109 120 -11 -9
Otsuka TS-1 Tegafur, Gimeracil, Oteracil Potassium Oncology YEN Millions 20,600 26,900 198 258 -60 -23
Otsuka UFT Tegafur Uracil Oncology YEN Millions 5,700 6,500 55 62 -8 -12
Otsuka Lonsurf Trifluridine and Tipiracil Oncology YEN Millions 32,600 30,100 313 289 24 8
Otsuka Bilanoa Bilastine Anti-allergic YEN Millions 2,000 2,200 19 21 -2 -9
Otsuka Aloxi Palonosetron Oncology YEN Millions 14,500 14,000 139 134 5 4
Otsuka Abraxane Paclitaxel Protein Bound Oncology YEN Millions 21,800 20,700 209 199 11 5
Otsuka E Keppra Levetiracetam Neurological/Mental Disorders YEN Millions 33,800 28,500 324 274 51 19
Otsuka Samsca/Jinarc Tolvaptan Cardiovascular Diseases YEN Millions 64,200 48,900 616 469 147 31
Otsuka Mucosta Ophthalmic Suspension Rebamipide Ophthalmology YEN Millions 5,100 4,800 49 46 3 6
Otsuka Neupro Patch Rotigotine Neurological/Mental Disorders YEN Millions 12,100 10,700 116 103 13 13
Otsuka Sprycel Dasatinib Oncology YEN Millions 30,800 29,300 296 281 14 5
Otsuka Zosyn/Tazocin Piperacillin and Tazobactam Anti-bacterial YEN Millions 6,300 8,800 60 84 -24 -28
Otsuka Diagnostics YEN Millions 12,800 13,700 123 132 -9 -7
Otsuka Parentral Nutrition YEN Millions 111,200 107,400 1,068 1,031 36 4
Otsuka Pharmaceutical Business Total (Excluding Export) YEN Millions 401,800 387,900 3,857 3,724 133 4
Otsuka Total Pharmaceuticals YEN Millions 774,800 753,005 7,438 7,229 209 3
Otsuka Total Nutraceuticals YEN Millions 326,200 311,550 3,132 2,991 141 5
Otsuka Total Consumer Products YEN Millions 35,600 35,468 342 340 1 0.4
Otsuka Others YEN Millions 151,100 141,251 1,451 1,356 95 7
Otsuka Total YEN Millions 1,287,700 1,241,274 12,362 11,916 446 4
Otsuka Corporate/Eliminations YEN Millions -47,800 -45,727 -459 -439 -20 5
Otsuka Total Consolidated YEN Millions 1,240,000 1,195,547 11,904 11,477 427 4
Pfizer Inc. Lyrica IH Pregabalin Neurological/Mental Disorders USD Millions 4,511 4,165 4,511 4,165 346 8
Pfizer Inc. Eliquis alliance revenues and direct sales Apixaban Cardiovascular Diseases USD Millions 2,523 1,713 2,523 1,713 810 47
Pfizer Inc. Chantix/Champix Varenicline Neurological/Mental Disorders USD Millions 997 842 997 842 155 18
Pfizer Inc. Viagra IH Sildenafil Citrate Sexual Health USD Millions 823 1,182 823 1,182 -359 -30
Pfizer Inc. BMP2 Bone Morphogenetic Proteins Bone and Joint Diseases USD Millions 261 251 261 251 10 4
Pfizer Inc. Toviaz Fesoterodine Fumarate Urology USD Millions 257 258 257 258 -1 -0.4
Pfizer Inc. All Other Internal Medicine USD Millions 312 447 312 447 -135 -30
Pfizer Inc. Internal Medicine USD Millions 9,684 8,858 9,684 8,858 826 9
Pfizer Inc. Prevnar 13/Prevenar 13 Pneumococcal 7-Valent Conjugate Anti-bacterial USD Millions 5,601 5,718 5,601 5,718 -117 -2
Pfizer Inc. FSME/IMMUN-TicoVac Tick-Borne Encephalitis Virus Immunology (Organ Transplant, Arthritis etc.) USD Millions 134 114 134 114 20 18
Pfizer Inc. All Other Vaccines USD Millions 266 239 266 239 27 11
Pfizer Inc. Vaccines USD Millions 6,001 6,070 6,001 6,070 -69 -1
Pfizer Inc. Ibrance Palbociclib Oncology USD Millions 3,126 2,136 3,126 2,136 990 46
Pfizer Inc. Sutent Sunitinib Malate Oncology USD Millions 1,081 1,096 1,081 1,096 -15 -1
Pfizer Inc. Xalkori Crizotinib Oncology USD Millions 594 560 594 560 34 6
Pfizer Inc. Xtandi Alliance Revenues Enzalutamide Oncology USD Millions 590 140 590 140 450 321
Pfizer Inc. Inlyta Axitinib Oncology USD Millions 339 401 339 401 -62 -15
Pfizer Inc. Bosulif Bosutinib Oncology USD Millions 233 167 233 167 66 40
Pfizer Inc. All Other Oncology USD Millions 93 64 93 64 29 45
Pfizer Inc. Oncology USD Millions 6,056 4,563 6,056 4,563 1,493 33
Pfizer Inc. Enbrel (Outside the U.S. and Canada) Etanercept Immunology (Organ Transplant, Arthritis etc.) USD Millions 2,452 2,910 2,452 2,910 -458 -16
Pfizer Inc. Xeljanz Tofacitinib Citrate Immunology (Organ Transplant, Arthritis etc.) USD Millions 1,345 927 1,345 927 418 45
Pfizer Inc. Eucrisa Crisaborole Dermatology USD Millions 67 0 67 0 67 New Launch
Pfizer Inc. All other I&I USD Millions 103 93 103 93 10 11
Pfizer Inc. Inflammation & Immunology USD Millions 3,968 3,928 3,968 3,928 40 1
Pfizer Inc. BeneFIX Coagulation Factor IX Rare Diseases USD Millions 604 712 604 712 -108 -15
Pfizer Inc. Refacto AF/Xyntha Antihemophilic Factor (Recombinant) Rare Diseases USD Millions 551 554 551 554 -3 -1
Pfizer Inc. Genotropin Somatropin Rare Diseases USD Millions 532 579 532 579 -47 -8
Pfizer Inc. Somavert Pegvisomant Hormonal Disorders USD Millions 254 233 254 233 21 9
Pfizer Inc. All Other Rare Diseases USD Millions 300 292 300 292 8 3
Pfizer Inc. Total Rare Diseases USD Millions 2,240 2,369 2,240 2,369 -129 -5
Pfizer Inc. Consumer Healthcare USD Millions 3,472 3,407 3,472 3,407 65 2
Pfizer Inc. Pfizer Innovative Health (IH) USD Millions 31,422 29,197 31,422 29,197 2,225 8
Pfizer Inc. Lipitor Atorvastatin Calcium Cardiovascular Diseases USD Millions 1,915 1,758 1,915 1,758 157 9
Pfizer Inc. Premarin family Conjugated Estrogens Sexual Health USD Millions 977 1,017 977 1,017 -40 -4
Pfizer Inc. Norvasc Amlodipine Cardiovascular Diseases USD Millions 926 962 926 962 -36 -4
Pfizer Inc. Xalatan/Xalacom Latanoprost Ophthalmology USD Millions 335 362 335 362 -27 -7
Pfizer Inc. Effexor Venlafaxine Neurological/Mental Disorders USD Millions 297 277 297 277 20 7
Pfizer Inc. Zoloft Sertraline Neurological/Mental Disorders USD Millions 291 304 291 304 -13 -4
Pfizer Inc. EpiPen Epinephrine Immunology (Organ Transplant, Arthritis etc.) USD Millions 290 386 290 386 -96 -25
Pfizer Inc. Zithromax/Zmax Azithromycin Anti-bacterial USD Millions 270 272 270 272 -2 -1
Pfizer Inc. Relpax Eletriptan Hydrobromide Neurological/Mental Disorders USD Millions 236 324 236 324 -88 -27
Pfizer Inc. Xanax/Xanax XR Alprazolam Neurological/Mental Disorders USD Millions 225 223 225 223 2 1
Pfizer Inc. Sildenafil Citrate Sildenafil Citrate Erectile Dysfunction USD Millions 56 0 56 0 56 New Launch
Pfizer Inc. All Other Legacy Established Products USD Millions 5,077 5,312 5,077 5,312 -235 -4
Pfizer Inc. Legacy Established Products USD Millions 10,894 11,197 10,894 11,197 -303 -3
Pfizer Inc. Celebrex Celecoxib Bone and Joint Diseases USD Millions 775 733 775 733 42 6
Pfizer Inc. Lyrica EH Pregabalin Neurological/Mental Disorders USD Millions 553 801 553 801 -248 -31
Pfizer Inc. Vfend Voriconazole Anti-fungal USD Millions 421 590 421 590 -169 -29
Pfizer Inc. Viagra EH Sildenafil Citrate Sexual Health USD Millions 382 383 382 383 -1 -0.3
Pfizer Inc. Pristiq Desvenlafaxine Neurological/Mental Disorders USD Millions 303 732 303 732 -429 -59
Pfizer Inc. Zyvox Linezolid Anti-bacterial USD Millions 281 421 281 421 -140 -33
Pfizer Inc. Revatio Sildenafil Cardiovascular Diseases USD Millions 252 285 252 285 -33 -12
Pfizer Inc. All other Peri-LOE Products USD Millions 257 275 257 275 -18 -7
Pfizer Inc. Peri-LOE Products USD Millions 3,223 4,220 3,223 4,220 -997 -24
Pfizer Inc. Medrol Methylprednisolone Immunology (Organ Transplant, Arthritis etc.) USD Millions 483 450 483 450 33 7
Pfizer Inc. Sulperazon Cefoperazone and Sulbactam Urology USD Millions 471 396 471 396 75 19
Pfizer Inc. Fragmin Dalteparin Blood Disorders USD Millions 306 318 306 318 -12 -4
Pfizer Inc. Tygacil Tigecycline Anti-bacterial USD Millions 260 274 260 274 -14 -5
Pfizer Inc. Precedex Dexmedetomidine Neurological/Mental Disorders USD Millions 243 264 243 264 -21 -8
Pfizer Inc. Zosyn/Tazocin Piperacillin/Tazobactam Anti-bacterial USD Millions 194 145 194 145 49 34
Pfizer Inc. All Other Sterile Injectable Pharmaceuticals USD Millions 3,715 4,165 3,715 4,165 -450 -11
Pfizer Inc. Sterile Injectable Pharmaceuticals USD Millions 5,673 6,016 5,673 6,016 -343 -6
Pfizer Inc. Inflectra/Remsima Infliximab Immunology (Organ Transplant, Arthritis etc.) USD Millions 419 192 419 192 227 118
Pfizer Inc. All Other Biosimilars USD Millions 112 127 112 127 -15 -12
Pfizer Inc. Biosimilars USD Millions 531 319 531 319 212 66
Pfizer Inc. Pfizer CentreOne USD Millions 706 719 706 719 -13 -2
Pfizer Inc. Hospira Infusion Systems USD Millions 97 1,158 97 1,158 -1,061 -92
Pfizer Inc. Total Lyrica Pregabalin Neurological/Mental Disorders USD Millions 5,065 4,967 5,065 4,967 98 2
Pfizer Inc. Total Viagra Sildenafil Citrate Sexual Health USD Millions 1,204 1,565 1,204 1,565 -361 -23
Pfizer Inc. Total Alliance Revenues USD Millions 2,927 1,745 2,927 1,745 1,182 68
Pfizer Inc. Pfizer Essential Health (EH) USD Millions 21,124 23,626 21,124 23,626 -2,502 -11
Pfizer Inc. Total Revenues USD Millions 52,546 52,824 52,546 52,824 -278 -1
Regeneron Eylea (In United States) Aflibercept Ophthalmology USD Millions 3,702 3,323 3,702 3,323 379 11
Regeneron Arcalyst Rilonacept Immunology (Organ Transplant, Arthritis etc.) USD Millions 16 15 16 15 1 7
Regeneron Net product Sales Recorded by Regeneron USD Millions 3,718 3,338 3,718 3,338 380 11
Regeneron EYLEA Outside of the United States Aflibercept Ophthalmology USD Millions 2,227 1,872 2,227 1,872 355 19
Regeneron EYLEA Global Aflibercept Ophthalmology USD Millions 5,929 5,195 5,929 5,195 734 14
Regeneron Praluent Alirocumab Cardiovascular Diseases USD Millions 195 116 195 116 79 68
Regeneron Dupixent Dupilumab Dermatology USD Millions 256 New Launch 256 New Launch 256 New Launch
Regeneron Kevzara Sarilumab Rheumatoid Arthritis USD Millions 13 New Launch 13 New Launch 13 New Launch
Regeneron Zaltrap Aflibercept Oncology USD Millions 84 72 84 72 12 17
Regeneron Sanofi Collaboration Revenue USD Millions 877 659 877 659 218 33
Regeneron Bayer Collaboration Revenue USD Millions 938 744 938 744 194 26
Regeneron Other Revenue USD Millions 339 119 339 119 220 185
Regeneron Total Revenues USD Millions 5,872 4,860 5,872 4,860 1,012 21
Roche Avastin Bevacizumab Oncology CHF Millions 6,688 6,783 7,089 7,190 -101 -1
Roche Herceptin Trastuzumab Oncology CHF Millions 7,014 6,782 7,435 7,189 246 3
Roche MabThera/Rituxan Rituximab Oncology CHF Millions 5,832 5,823 6,182 6,172 10 0.2
Roche Tarceva Erlotinib Oncology CHF Millions 843 1,024 894 1,085 -192 -18
Roche Perjeta Pertuzumab Oncology CHF Millions 2,196 1,846 2,328 1,957 371 19
Roche Tecentriq Atezolizumab Oncology CHF Millions 487 157 516 166 350 210
Roche Xeloda Capecitabine Oncology CHF Millions 453 506 480 536 -56 -10
Roche Kadcyla Trastuzumab Emtansine Oncology CHF Millions 914 831 969 881 88 10
Roche Alecensa Alectinib Oncology CHF Millions 362 182 384 193 191 99
Roche Gazyva/Gazyvaro Obinutuzumab Oncology CHF Millions 278 196 295 208 87 42
Roche Others CHF Millions 676 711 717 754 -37 -5
Roche Total Oncology CHF Millions 25,743 24,841 27,288 26,331 956 4
Roche MabThera/Rituxan Rituximab Oncology CHF Millions 1,556 1,477 1,649 1,566 84 5
Roche Actemra/RoActemra Tocilizumab Immunology (Organ Transplant, Arthritis etc.) CHF Millions 1,926 1,697 2,042 1,799 243 13
Roche Xolair Omalizumab Immunology (Organ Transplant, Arthritis etc.) CHF Millions 1,742 1,498 1,847 1,588 259 16
Roche CellCept Mycophenolate Mofetil Immunology (Organ Transplant, Arthritis etc.) CHF Millions 697 741 739 785 -47 -6
Roche Pulmozyme Dornase Alfa Rare Diseases CHF Millions 730 685 774 726 48 7
Roche Esbriet Pirfenidone Idiopathic Pulmonary Fibrosis CHF Millions 869 768 921 814 107 13
Roche Others CHF Millions 91 104 96 110 -14 -13
Roche Total Immunology CHF Millions 7,611 6,970 8,068 7,388 679 9
Roche Pegasys Peginterferon Alfa-2a Infectious Diseases (HIV, Hepatitis etc.) CHF Millions 178 259 189 275 -86 -31
Roche Tamiflu Oseltamivir Phosphate Infectious Diseases (HIV, Hepatitis etc.) CHF Millions 535 794 567 842 -275 -33
Roche Valcyte/Cymevene Ganciclovir and Valganciclovir Immunology (Organ Transplant, Arthritis etc.) CHF Millions 235 306 249 324 -75 -23
Roche Rocephin Ceftriaxone Neurological/Mental Disorders CHF Millions 299 298 317 316 1 0.3
Roche Others CHF Millions 110 116 117 123 -6 -5
Roche Total Infectious Diseases CHF Millions 1,357 1,773 1,438 1,879 -441 -23
Roche Lucentis Ranibizumab Ophthalmology CHF Millions 1,414 1,406 1,499 1,490 8 1
Roche Total Opthalmology CHF Millions 1,414 1,406 1,499 1,490 8 1
Roche Madopar Levodopa and Benserazide Neurological/Mental Disorders CHF Millions 334 290 354 307 47 15
Roche Ocrevus Ocrelizumab Neurological/Mental Disorders CHF Millions 869 0 921 0 921 New Launch
Roche Others CHF Millions 339 367 359 389 -30 -8
Roche Total Neuroscience CHF Millions 1,542 657 1,635 696 938 135
Roche Activase/TNKase Alteplase/Tenecteplase Cardiovascular Diseases CHF Millions 1,219 1,108 1,292 1,174 118 10
Roche NeoRecormon/Epogin Epoetin Beta and Epoetin Alfa Blood Disorders CHF Millions 312 328 331 348 -17 -5
Roche Mircera Methoxy Polyethylene Glycol and Epoetin Beta Blood Disorders CHF Millions 505 512 535 543 -7 -1
Roche Others CHF Millions 1,517 1,508 1,608 1,598 10 1
Roche Total Other Therapeutic Areas CHF Millions 3,553 3,456 3,766 3,663 103 3
Roche Total Sales CHF Millions 41,220 39,103 43,693 41,449 2,244 5
Roche Royalties and Other Operating Income CHF Millions 2,284 1,944 2,421 2,061 360 17
Roche Total Pharmaceutical Sales CHF Millions 43,504 41,047 46,114 43,510 2,604 6
Roche Diagnostic Division CHF Millions 12,079 11,473 12,804 12,161 642 5
Roche Royalties and Other Operating Income CHF Millions 163 116 173 123 50 41
Roche Total Diagnostic Sales CHF Millions 12,242 11,589 12,977 12,284 692 6
Roche Total Group Sales CHF Millions 55,746 52,636 59,091 55,794 3,297 6
Sanofi Cerezyme Imiglucerase Rare Diseases EURO Millions 730 748 905 928 -22 -2
Sanofi Cerdelga Eliglustat Rare Diseases EURO Millions 126 106 156 131 25 19
Sanofi Myozyme/Lumizyme Alglucosidase Alfa Rare Diseases EURO Millions 789 725 978 899 79 9
Sanofi Fabrazyme Agalsidase Beta Rare Diseases EURO Millions 722 674 895 836 60 7
Sanofi Aldurazyme Laronidase Rare Diseases EURO Millions 207 201 257 249 7 3
Sanofi Other Rare Diseases Products EURO Millions 314 323 389 401 -11 -3
Sanofi Total Rare Diseases EURO Millions 2,888 2,777 3,581 3,443 138 4
Sanofi Aubagio Teriflunomide Neurological/Mental Disorders EURO Millions 1,567 1,295 1,943 1,606 337 21
Sanofi Lemtrada Alemtuzumab Neurological/Mental Disorders EURO Millions 474 425 588 527 61 12
Sanofi Total Multiple Sclerosis EURO Millions 2,041 1,720 2,531 2,133 398 19
Sanofi Jevtana Cabazitaxel Oncology EURO Millions 386 358 479 444 35 8
Sanofi Thymoglobulin Anti-thymocyte Globulin Immunology (Organ Transplant, Arthritis etc.) EURO Millions 291 281 361 348 12 4
Sanofi Taxotere Docetaxel Oncology EURO Millions 173 179 215 222 -7 -3
Sanofi Eloxatine Oxaliplatin Oncology EURO Millions 179 170 222 211 11 5
Sanofi Mozobil Plerixafor Oncology EURO Millions 163 152 202 188 14 7
Sanofi Zaltrap Aflibercept Oncology EURO Millions 75 65 93 81 12 15
Sanofi Other Oncology EURO Millions 252 248 312 308 5 2
Sanofi Total Oncology EURO Millions 1,519 1,453 1,884 1,802 82 5
Sanofi Dupixent Dupilumab Dermatology EURO Millions 219 0 272 0 272 New Launch
Sanofi Kevzara Sarilumab Rheumatoid Arthritis EURO Millions 11 0 14 0 14 New Launch
Sanofi Total Immunology EURO Millions 230 0 285 0 285 100
Sanofi Sanofi Genzyme (Speciality Care) EURO Millions 6,678 5,950 8,281 7,378 903 12
Sanofi Lantus Insulin Glargine Diabetes EURO Millions 4,622 5,714 5,731 7,085 -1,354 -19
Sanofi Toujeo Insulin Glargine Diabetes EURO Millions 816 649 1,012 805 207 26
Sanofi Apidra Insulin Glulisine Diabetes EURO Millions 377 367 467 455 12 3
Sanofi Amaryl Glimepiride Diabetes EURO Millions 337 362 418 449 -31 -7
Sanofi Insuman Insulin Diabetes EURO Millions 107 129 133 160 -27 -17
Sanofi Lyxumia Lixisenatide Diabetes EURO Millions 26 33 32 41 -9 -21
Sanofi Soliqua Insulin Glargine and Lixisenatide Diabetes EURO Millions 26 0 32 0 32 New Launch
Sanofi Other Diabetes Products EURO Millions 84 87 104 108 -4 -3
Sanofi Total Diabetes EURO Millions 6,395 7,341 7,930 9,103 -1,173 -13
Sanofi Multaq Dronedarone Cardiovascular Diseases EURO Millions 339 353 420 438 -17 -4
Sanofi Praluent Alirocumab Cardiovascular Diseases EURO Millions 171 105 212 130 82 63
Sanofi Total Cardiovascular EURO Millions 510 458 632 568 64 11
Sanofi Total Diabetes & Cardiovascular EURO Millions 6,905 7,799 8,562 9,671 -1,109 -11
Sanofi Lovenox Enoxaparin Sodium Blood Disorders EURO Millions 1,575 1,636 1,953 2,029 -76 -4
Sanofi Plavix Clopidogrel Bisulfate Cardiovascular Diseases EURO Millions 1,471 1,544 1,824 1,915 -91 -5
Sanofi Renagel/Renvela Sevelamer Hydrochloride and Sevelamer Carbonate Urology EURO Millions 802 922 994 1,143 -149 -13
Sanofi Aprovel Irbesartan/Irbesartan + Hydrochlorothiazide Cardiovascular Diseases EURO Millions 691 681 857 844 12 1
Sanofi Depakine Valproate Sodium Neurological/Mental Disorders EURO Millions 443 416 549 516 33 6
Sanofi Synvisc/Synvisc One Hylan G-F 20 Bone and Joint Diseases EURO Millions 387 408 480 506 -26 -5
Sanofi Allegra Fexofenadine Hydrochoride Respiratory Disorders EURO Millions 158 186 196 231 -35 -15
Sanofi Myslee/Ambien/Stilnox Zolpidem Neurological/Mental Disorders EURO Millions 259 304 321 377 -56 -15
Sanofi Tritace Ramipril Cardiovascular Diseases EURO Millions 241 245 299 304 -5 -2
Sanofi Targocid Teicoplanin Anti-bacterial EURO Millions 130 149 161 185 -24 -13
Sanofi Lasix Furosemide Cardiovascular Diseases EURO Millions 137 148 170 184 -14 -7
Sanofi Other Rx Drugs EURO Millions 3,467 3,672 4,299 4,553 -254 -6
Sanofi Total Established Rx Products EURO Millions 9,761 10,311 12,104 12,786 -682 -5
Sanofi Generics EURO Millions 1,778 1,854 2,205 2,299 -94 -4
Sanofi Total Emerging Markets – Specialty/Care EURO Millions 1,004 931 1,245 1,154 91 8
Sanofi Total Emerging Markets –nDiabetes & Cardiovascular EURO Millions 1,505 1,402 1,866 1,738 128 7
Sanofi General Medicine & Emerging Market EURO Millions 14,048 14,498 17,420 17,978 -558 -3
Sanofi Total Pharmaceuticals EURO Millions 25,122 25,914 31,151 32,133 -982 -3
Sanofi Consumer Healthcare EURO Millions 4,832 3,330 5,992 4,129 1,862 45
Sanofi Polio/Pertussis/Hib EURO Millions 1,827 1,495 2,265 1,854 412 22
Sanofi Influenza Vaccines EURO Millions 1,589 1,521 1,970 1,886 84 4
Sanofi Meningitis/Pneumonia EURO Millions 623 633 773 785 -12 -2
Sanofi Travel And Other Endemics Vaccines EURO Millions 493 368 611 456 155 34
Sanofi Adult Booster Vaccines EURO Millions 474 417 588 517 71 14
Sanofi Dengvaxia EURO Millions 3 55 4 68 -64 -95
Sanofi Other Vaccines EURO Millions 92 88 114 109 5 5
Sanofi Vaccines EURO Millions 5,101 4,577 6,325 5,675 650 11
Sanofi Total Group EURO Millions 35,055 33,821 43,468 41,938 1,530 4
Sanofi Companion Animals EURO Millions 0 1,781 0 2,208 -2,208 -100
Sanofi Production Animals EURO Millions 0 927 0 1,149 -1,149 -100
Sanofi Total Animal Health EURO Millions 0 2,708 0 3,358 -3,358 -100
Sanofi Total Aggregate Group Sales EURO Millions 35,055 36,529 43,468 45,296 -1,828 -4
Shire Elaprase Idursulfase Rare Diseases USD Millions 615 589 615 589 26 4
Shire Replagal Agalsidase Alfa Rare Diseases USD Millions 473 452 473 452 20 5
Shire Vpriv Velaglucerase Alfa Rare Diseases USD Millions 349 346 349 346 3 1
Shire Genetic Diseases USD Millions 1,438 1,387 1,438 1,387 51 4
Shire Vyvanse Lisdexamfetamine Dimesylate Neurological/Mental Disorders USD Millions 2,161 2,014 2,161 2,014 147 7
Shire Adderall XR Amphetamine, Dextroamphetamine Neurological/Mental Disorders USD Millions 348 364 348 364 -16 -4
Shire Mydayis Mixed Salts of a Single-Entity Amphetamine Neurological/Mental Disorders USD Millions 22 0 22 0 22 New Launch
Shire Other Neuroscience USD Millions 133 113 133 113 21 18
Shire Neuroscience USD Millions 2,664 2,491 2,664 2,491 174 7
Shire Hemophilia USD Millions 2,957 1,789 2,957 1,789 1,168 65
Shire Inhibitor Therapies USD Millions 828 452 828 452 377 83
Shire Hematology USD Millions 3,786 2,241 3,786 2,241 1,545 69
Shire Lialda/Mezavant Mesalamine Anti-inflammatory USD Millions 569 792 569 792 -223 -28
Shire Pentasa Mesalazine Gastrointestinal Disorders USD Millions 313 309 313 309 4 1
Shire Gattex/Revestive Teduglutide Gastrointestinal Disorders USD Millions 336 219 336 219 116 53
Shire Natpara Parathyroid Hormone Hormonal Disorders USD Millions 147 85 147 85 62 73
Shire Other Internal Medicine USD Millions 305 349 305 349 -45 -13
Shire Internal Medicine USD Millions 1,670 1,756 1,670 1,756 -85 -5
Shire Immunoglobulin Therapies USD Millions 2,237 1,144 2,237 1,144 1,093 96
Shire Cinryze Complement C1 esterase Immunology (Organ Transplant, Arthritis etc.) USD Millions 699 680 699 680 19 3
Shire Firazyr Icatibant Rare Diseases USD Millions 663 579 663 579 85 15
Shire Kalbitor Ecallantide Dermatology USD Millions 67 52 67 52 15 29
Shire Bio Therapeutics USD Millions 704 372 704 372 332 89
Shire Immunology USD Millions 4,370 2,827 4,370 2,827 1,543 55
Shire Oncology USD Millions 262 131 262 131 131 101
Shire Ophthalmology USD Millions 259 54 259 54 205 376
Shire Total Product Sales USD Millions 14,449 10,886 14,449 10,886 3,563 33
Shire Total Royalties and Other Revenues USD Millions 712 511 712 511 201 39
Shire Total Revenues USD Millions 15,161 11,397 15,161 11,397 3,764 33
Takeda Adcetris Brentuximab Vedotin Oncology YEN Millions 37,200 28,100 357 270 87 32
Takeda Amitiza Lubiprostone Gastrointestinal Disorders YEN Millions 34,500 34,500 331 331 0 0.0
Takeda Uloric Febuxostat Rheumatoid Arthritis YEN Millions 46,200 41,900 444 402 41 10
Takeda Colcrys Colchicine Anti-inflammatory YEN Millions 41,500 41,800 398 401 -3 -1
Takeda Nesina Alogliptin Diabetes YEN Millions 52,200 48,700 501 468 34 7
Takeda Azilva Azilsartan Cardiovascular Diseases YEN Millions 71,800 65,700 689 631 59 9
Takeda Dexilant Dexlansoprazole Gastrointestinal Disorders YEN Millions 67,700 65,500 650 629 21 3
Takeda Candesartan Candesartan Cardiovascular Diseases YEN Millions 24,500 45,300 235 435 -200 -46
Takeda Entyvio Vedolizumab Anti-inflammatory YEN Millions 189,900 129,700 1,823 1,245 578 46
Takeda Prevacid/Lansoprazole Lansoprazole Gastrointestinal Disorders YEN Millions 38,600 53,400 371 513 -142 -28
Takeda Pantoprazole Pantoprazole Gastrointestinal Disorders YEN Millions 67,000 78,800 643 756 -113 -15
Takeda Leuprorelin Leuprorelin Oncology YEN Millions 114,000 116,700 1,094 1,120 -26 -2
Takeda Velcade Bortezomib Oncology YEN Millions 141,900 139,100 1,362 1,335 27 2
Takeda Ninlaro Ixazomib Oncology YEN Millions 43,100 20,800 414 200 214 107
Takeda Takecab Vonoprazan Fumarate Gastrointestinal Disorders YEN Millions 51,500 30,700 494 295 200 68
Takeda Brintellix/Trintellix Vortioxetine Neurological/Mental Disorders YEN Millions 46,700 29,200 448 280 168 60
Takeda Lotriga Omega-3-acid Ethyl Esters Cardiovascular Diseases YEN Millions 31,200 26,600 300 255 44 17
Takeda Vectibix Panitumumab Oncology YEN Millions 19,200 18,800 184 180 4 2
Takeda Reminyl Galantamine Neurological/Mental Disorders YEN Millions 17,900 17,200 172 165 7 4
Takeda Enbrel Etanercept Immunology (Organ Transplant, Arthritis etc.) YEN Millions 39,300 40,700 377 391 -13 -3
Takeda Benet Risedronate Sodium Hydrate Bone and Joint Diseases YEN Millions 7,700 8,600 74 83 -9 -10
Takeda Rozerem Ramelteon Neurological/Mental Disorders YEN Millions 8,800 7,900 84 76 9 11
Takeda Alinamin Fursultiamine Nutritional Deficiency YEN Millions 25,900 23,800 249 228 20 9
Takeda Alinamin Health Tonic Fursultiamine Nutritional Deficiency YEN Millions 15,100 15,800 145 152 -7 -4
Takeda Biofermin Bifidobacterium Gastrointestinal Disorders YEN Millions 6,200 7,200 60 69 -10 -14
Takeda Benza Isopropamide Iodide Anti-cholinergic YEN Millions 9,600 11,700 92 112 -20 -18
Takeda Borraginol Prednisolone Acetate, Lidocaine, Allantoin and Vitamin E Hemorrhoids YEN Millions 4,600 4,500 44 43 1 2
Takeda Mytear YEN Millions 2,600 0 25 0 25 New Launch
Takeda Others YEN Millions 530,000 698,000 5,088 6,701 -1,613 -24
Takeda Total Revenues YEN Millions 1,786,000 1,851,200 17,146 17,772 -626 -4
Teva Copaxone Glatiramer Acetate Neurological/Mental Disorders USD Millions 3,801 4,223 3,801 4,223 -422 -10
Teva Azilect Rasagiline Neurological/Mental Disorders USD Millions 170 410 170 410 -240 -59
Teva Nuvigil Armodafinil Neurological/Mental Disorders USD Millions 61 200 61 200 -139 -70
Teva Others USD Millions 394 450 394 450 -56 -12
Teva Total Neuroscience USD Millions 4,426 5,283 4,426 5,283 -857 -16
Teva Treanda and Bendeka Bendamustine Oncology USD Millions 658 661 658 661 -3 -0.5
Teva Others USD Millions 477 478 477 478 -1 -0.2
Teva Total Oncology USD Millions 1,135 1,139 1,135 1,139 -4 -0.4
Teva ProAir Albuterol Sulfate Respiratory Disorders USD Millions 501 565 501 565 -64 -11
Teva Qvar Beclomethasone Respiratory Disorders USD Millions 361 462 361 462 -101 -22
Teva Others USD Millions 408 247 408 247 161 65
Teva Total Respiratory USD Millions 1,270 1,274 1,270 1,274 -4 -0.3
Teva Women’s Health USD Millions 426 458 426 458 -32 -7
Teva Other Specialilty Medicines USD Millions 657 520 657 520 137 26
Teva Speciality Medicines USD Millions 7,914 8,674 7,914 8,674 -760 -9
Teva All Others USD Millions 2,214 1,239 2,214 1,239 975 79
Teva Generic Medicines USD Millions 12,257 11,990 12,257 11,990 267 2
Teva Total Sales USD Millions 22,385 21,903 22,385 21,903 482 2
Valeant Pharmaceuticals Bausch + Lomb/International USD Millions 4,871 4,927 4,871 4,927 -56 -1
Valeant Pharmaceuticals Branded Rx USD Millions 2,475 2,828 2,475 2,828 -353 -12
Valeant Pharmaceuticals Wellbutrin Bupropion Neurological/Mental Disorders USD Millions 234 279 234 279 -45 -16
Valeant Pharmaceuticals Xenazine Tetrabenazine Rare Diseases USD Millions 113 157 113 157 -44 -28
Valeant Pharmaceuticals Isuprel Isoprenaline Cardiovascular Diseases USD Millions 105 178 105 178 -73 -41
Valeant Pharmaceuticals Syprine Trientine Hydrochloride Genetic Disorders USD Millions 91 88 91 88 3 3
Valeant Pharmaceuticals Cuprimine Penicillamine Rare Diseases USD Millions 78 104 78 104 -26 -25
Valeant Pharmaceuticals Ativan Lorazepam Neurological/Mental Disorders USD Millions 60 41 60 41 19 46
Valeant Pharmaceuticals Migranal Dihydroergotamine Mesylate Neurological/Mental Disorders USD Millions 53 54 53 54 -1 -2
Valeant Pharmaceuticals Mephyton Phytonadione Blood Disorders USD Millions 51 56 51 56 -5 -9
Valeant Pharmaceuticals Glumetza Metformin Hydrochloride Diabetes USD Millions 39 67 39 67 -28 -42
Valeant Pharmaceuticals Aplenzin Bupropion Hydrobromide Neurological/Mental Disorders USD Millions 31 42 31 42 -11 -26
Valeant Pharmaceuticals Other Products Revenues USD Millions 509 900 509 900 -391 -43
Valeant Pharmaceuticals Other Revenues USD Millions 14 20 14 20 -6 -30
Valeant Pharmaceuticals Total U.S. Diversified Revenues USD Millions 1,378 1,919 1,378 1,919 -541 -28
Valeant Pharmaceuticals Total Revenues USD Millions 8,724 9,674 8,724 9,674 -950 -10
Vertex Kalydeco Ivacaftor Respiratory Disorders USD Millions 845 703 845 703 142 20
Vertex Orkambi Lumacaftor/Ivacaftor Respiratory Disorders USD Millions 1,321 980 1,321 980 341 35
Vertex Total Product Revenues USD Millions 2,166 1,683 2,166 1,683 483 29
Vertex Royalty Revenues USD Millions 8 17 8 17 -9 -52
Vertex Collaborative Revenues USD Millions 316 2 316 2 314 16,173
Vertex Total Sales USD Millions 2,490 1,702 2,490 1,702 788 46

Continue at:  https://www.pharmacompass.com/data-compilation/product-sales-data-from-annual-reports-of-major-pharmaceutical-companies-2017

The text above is owned by the site above referred.

Here is only a small part of the article, for more please follow the link

Also see:

https://dadoswebaxx.weebly.com/

DadosWebaxx
DadosWebAxx

Leave a Reply

Your email address will not be published. Required fields are marked *